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ABSTRACT OF THE DISSERTATION
The Effects of Molecular Chaperone Modulation on Protein Folding, Prion Formation, and Prion
Propagation in Saccharomyces cerevisiae
by
Leeran Blythe Dublin Ryan
Doctor of Philosophy in Biology and Biomedical Sciences
Developmental, Regenerative, and Stem Cell Biology
Washington University in St. Louis, 2021
Professor Heather True, Chair
Proper and efficient protein folding is vital for cell survival. Many factors affect protein
folding fidelity and prion formation, including molecular chaperone availability and activity.
Research has shown that modulating chaperone availability and function can affect protein
misfolding and aggregation, as well as de novo prion formation and propagation. However, the
factors involved and underlying mechanisms influencing prion formation and protein folding are
largely unknown. The following work aims to elucidate these areas.
The Nascent Polypeptide-Associated Complex (NAC) is the first point of chaperone
contact for nascent polypeptides. Previous work has shown that disruption of the NAC leads to
improved viability in cells experiencing protein misfolding stress. This counterintuitive result
led us to investigate the ability of NAC deletion to improve survivability of cells expressing
misfolding human proteins. This work resulted in the identification of multiple NAC deletion
strains that improve viability in cells expressing disease-causing alpha-synuclein and expanded
polyglutamine proteins. Also, this work identified changes in de novo induction of a yeast prion
and morphological changes in expanded polyglutamine aggregates as a result of NAC disruption.

xvii

Overall, this work reveals the potential of NAC disruption as a therapeutic target for
neurodegenerative diseases and sets the stage for investigating the mechanism by which NAC
disruption improves viability in cells expressing disease-causing, aggregating proteins.
Mutations in another chaperone, DNAJB6, have been shown to cause Limb-Girdle
Muscular Dystrophy Type 1D (LGMDD1). While we know that these mutations are associated
with LGMDD1, the mechanism by which they induce disease remains unknown. Because
substrates of DNAJB6 have not been identified, we have turned to a homologous protein in
yeast, Sis1, with known client proteins to better understand the effect of these mutations. We
have also developed a Sis1-DNAJB6 chimeric protein (SDSS) to evaluate these mutations. This
chimeric protein includes the J, G/M, and C-terminal domains of Sis1, and the G/F domain, in
which many LGMDD1-associated mutations are found, of DNAJB6. Previous work has shown
that when LGMDD1-associated mutations are introduced in Sis1 or SDSS there is disruption of
client processing by Sis1. This body of work identifies multiple second-site suppressors that,
when introduced in combination with LGMDD1-associated mutations, are capable of recovering
client processing by Sis1 and SDSS. Overall, this work shows that second-site suppressors may
be capable of recovering DNAJB6 activity when introduced in combination with LGMDD1associated mutations. Moreover, it provides an experimental model for the continued
investigation of these second-site suppressors and identification of similar therapeutic avenues
for potentially treating patients with other LGMDD1-associated mutations in the future.
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Chapter 1: Background and Significance

1

1.1 Overview
Proteins must achieve particular folds in order to participate in normal cellular
functions. This process is integral to maintaining life. Molecular chaperones facilitate proper
protein folding both co- and post-translationally. Modulation of expression and activity of these
molecular chaperones can alter the protein folding environment. This can lead to protein
misfolding and aggregation in a subset of diseases called chaperonopathies. Protein misfolding
and aggregation often induces diseases such as Huntington’s Disease, certain forms of muscular
dystrophy, Alzheimer’s Disease, and many others. Significant questions remain on how proper
protein folding is achieved, what causes de novo protein misfolding and aggregation, what
changes in molecular chaperones can be tolerated or beneficial to cells, and how diseases caused
by molecular chaperone perturbations can be successfully treated. This dissertation seeks to
better understand how molecular chaperone modulation can change the protein folding landscape
and identify potential strategies for restoring molecular chaperone activity in disease-causing
mutants.

1.2 Protein Folding
1.2.1 Protein Translation
Proper protein folding is vital for virtually all cellular processes and, thus, for cell
survival. Saccharomyces cerevisiae has provided a robust and tractable model system for
studying protein translation and folding. Therefore, the processing of proteins will herein be
described within this model organism unless otherwise stated. Every protein is created through
translation of messenger RNA (mRNA) by the ribosome. The ribosome reads each triplet of
nucleic acid code, fits a tRNA to that unique code, and a corresponding amino acid is added to a
chain of previously decoded amino acids, known as a polypeptide. This process creates long
2

chains of amino acids that must then be folded to create a functional protein. As shown in Figure
1.1A, proteins sample many different fold conformations and adopt folds that reduce free energy.
Molecular chaperones facilitate this sampling and promote protein folding to the native and
functional state.

1.2.2 Co-translational and post-translational protein folding
As the ribosome decodes mRNA and amino acids are added, the polypeptide elongates
through the ribosome exit tunnel and has been shown to adopt various folds within the ribosome
itself (Woolhead et al., 2004; Lu & Deutsch, 2005; Kosolapov & Deutsch, 2009; Wruck et al.,
2021). As the protein emerges from the ribosome there are multiple factors poised to interact
with the nascent polypeptide (Figure 1.1B). First, the nascent polypeptide associate complex
(NAC) binds to the amino acid chain to prevent errant binding or folding of the polypeptide in
the crowded cytosolic landscape. In fact, research has shown that the NAC extends into the
ribosome exit tunnel and binds to polypeptides as short as two amino acids to begin this process
even before the polypeptide exits the ribosome (Gamerdinger et al., 2019). Furthermore, the
NAC is involved in targeting proteins to the mitochondria, as the NAC has been shown to
interact with mitochondrial translocation complexes TOM and SAM (Ponce-Rojas et al., 2017).
Second, other factors bound to the ribosome come into contact with the nascent polypeptide. The
signal recognizing particle (SRP) is one such factor. Polypeptides containing a signal sequence
are bound and recognized by SRP, which then initiates the transport of the ribosome-nascent
chain complex (RNC) to the endoplasmic reticulum (ER). There, SRP binds to the signal
recognition particle receptor (SR) and recruits Sec61p, which will coordinate translocation of the
protein into the ER. Other protein folding chaperones, such as SSB, interact with the emerging
polypeptide as well. SSB is an Hsp70 protein that associates with the ribosome and interacts with
3

nascent polypeptides to assist with co-translational folding (Willmund et al., 2013). SSB
association with the ribosome and binding to nascent polypeptides is greatly enhanced by the
presence of the ribosome-associated complex (RAC) which is composed of an Hsp40, Zuo1, and
an Hsp70, Ssz (Gumiero et al., 2016). The RAC interacts with SSB and stimulates ATP
hydrolysis by SSB. The RAC binds directly to the ribosome near the ribosome exit tunnel,
suggesting the RAC and SSB are important for co-translational protein folding. Recent research
has shown that some protein complexes assemble during translation, revealing a role for protein
complex binding partners in co-translational protein folding (Shiber et al., 2018). Simultaneous
deletion of multiple co-translational components (namely the NAC and SSB) results in drastic
growth defects, showing that the roles of these factors overlap and further cementing the
importance of co-translational protein folding in proteostasis (Koplin et al., 2010).
As proteins are continuously sampling various folding conformations there is not a clear
demarcation between co- and post-translational folding. Instead there is a spectrum of molecular
chaperone interactions that are at one end almost exclusively involved in early co-translational
folding, at the other almost exclusively involved in post-translational folding, and in the middle
participating in both stages of protein folding. Hsp70s and Hsp40s are molecular chaperone
proteins that work together to bind and fold a variety of polypeptides, both associated with the
ribosome and downstream of translational machinery. Hsp70s directly bind folding
intermediates, while Hsp40s are cochaperones that regulate the protein binding activity of
Hsp70s. Hsp40s are also known as J-proteins, as they all have a J-domain that is responsible for
interacting directly with the Hsp70 nucleotide binding domain (NBD) (Craig & Marszalek et al.,
2014). This interaction stimulates hydrolysis of an Hsp70 bound ATP to ADP, which triggers the
Hsp70 to stably bind the folding intermediate substrate in its closed state. After this, a nucleotide
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exchange factor (NEF), another cochaperone, binds to the Hsp70 and catalyzes exchange of the
bound ADP for an ATP, which triggers the release of the substrate. This sudden release of the
protein allows spontaneous folding to occur. Proteins that require additional folding after
interactions with the Hsp70-Hsp40 system are recruited to cylindrical chaperonin complexes by
an ATP-independent chaperone known as prefoldin (Kim et al., 2013). Chaperonin complexes
are ATP-dependent, large, hollow, double-ring structures that encapsulate nascent proteins,
allowing them to fold in a controlled environment away from the crowded and somewhat chaotic
protein folding environment within the cytosol (Kim et al., 2013). Chaperonins are composed of
several subunits per ring (seven to nine) and there are two groups chaperonins are classified as,
separated by their requirement for a lid-shaped cochaperone and differences in the composition
of their ring structures (Frydman, 2001, Kim at al., 2013). Group I chaperonins require lidshaped co-chaperones and include the bacterial chaperonin GroEL, the mitochondrial chaperonin
Hsp60, and the chloroplast chaperonin Cpn60 (Tilly et al., 1981; Kim et al., 2013). The lidshaped co-chaperones that interact with these Group I chaperonins are GroES, Hsp10, and
Cpn10/Cpn20, respectively (Kim et al., 2013).

Group II includes the archaea chaperonin

thermosome and the eukaryotic TRiC/CCT (TCP-1 ring complex/chaperonin-containing TCP-1)
chaperonin, both of which have lid domains. The TRiC/CCT chaperonin is known to participate
in co- and post-translational folding of many cytosolic proteins, including actin and tubulin,
which require the TRiC/CCT complex for folding (Llorca et al., 2000; Frydman, 2001).
Prefoldin, which has a heterohexameric structure in eukaryotes, binds to unfolded actin and
alpha and beta tubulin during translation and releases them when they have been delivered to
TRiC/CCT (Hansen et al., 1999). Interestingly, TRiC/CCT is known to interact with the Nterminus of mutant huntingtin, which includes the expanded polyglutamine sequence, in yeast
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and human cell culture and induces non-toxic aggregation of the protein (Behrends et al., 2006;
Tam et al., 2009). This interaction has been shown to reduce cytotoxicity of the protein
(Kitamura, et al., 2006; Tam et al., 2006).
Hsp90 (homologous to Hsp82 in Saccharomyces cerevisiae) is a posttranslational
molecular chaperone that interacts with nascent proteins as a homodimer. In eukaryotes, Hsp90
has three domains: a N-terminal domain, which has an essential ATP-binding site, a middle
domain that is required for substrate interaction and regulation of ATP hydrolysis, and a Cterminal domain that houses the interaction site that allows dimerization of the chaperone (Kim
et al., 2013). There are multiple co-chaperones that regulate Hsp90 activity. Hsp90 organizing
protein (HOP, homologous to Sti1 in yeast) has one domain each for interacting with Hsp70 and
Hsp90, which allows it to coordinate client protein transfer to the Hsp90 homodimer from the
Hsp70-Hsp40 system (Kim et al., 2013). HOP, as well as another co-chaperone, Cdc37, inhibits
the ATPase activity of the Hsp90 homodimer, which serves to stabilize the open conformation of
the complex (Prodromou et al., 1999; Siligardi et al., 2002, Roe et al., 2004). To balance this
system there are two co-chaperones, Hsp90 ATPase (Aha1), which binds first to one middle
domain, then to one N-terminal domain within the dimer, stimulating ATP hydrolysis and
transition to the closed state, and p23 (Sba1 in yeast), which binds to the N domains of the dimer
and stabilizes the closed ATP-bound state of the system (Retzlaff et al., 2010; Schopf et al.,
2017).
Finally, yeast have a AAA+ (ATPase Associated with diverse cellular Activities)
protein known as Hsp104 that acts as a disaggregase (Parsell et al., 1994). Hsp104 is a protein
with two nucleotide binding domains (NBD1 and NBD2) separated by a middle domain (MD)
and bookended by an amino-terminal domain (NTD) and a short carboxy-terminal domain
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(CTD) (Schirmer et al., 1996). Each of the NBD domains contain Walker motifs (Walker A and
Walker B) and an arginine finger residue, all of which are important for ATP binding and
hydrolysis (Sweeny and Shorter, 2016). The NBD domains also contain pore loops rich in
tyrosine residues that engage folding substrates (Sweeny and Shorter, 2016). The proximity of
these regions to one another couples ATP hydrolysis and the structural changes that occur as a
result with substrate refolding (Sweeny and Shorter, 2016). While some aspects of Hsp104
assembly and function are understood, much remains unknown. ADP or ATP binding by NBD2
is crucial for the hexameric complex to form, but NBD1 nucleotide binding is not required
(Parsell et al., 1994). Furthermore, it is known that Hsp104 disassembles both amorphous and
organized aggregate structures, though by different mechanisms. Amorphous aggregates can be
disassembled through non-cooperative activity of the hexamer subunits, however more
structured aggregates require cooperative activity of the hexamer subunits and substrates are
pulled partially or completely through the pore made by the hexamer structure (Lum et al. 2004,
2008; Haslberger et al. 2008; Tessarz et al. 2008; DeSantis et al, 2012; Sweeny et al. 2015; Gates
et al. 2017). Hsp104 is required for yeast [PSI+] prion propagation (along with propagation of
other yeast prions), as the hexameric complex formed by Hsp104 is thought to break large [PSI+]
aggregate structures into smaller oligomers or prion seeds that can be passed through the budding
neck to daughter cells (Romanova and Chernoff, 2010).

1.2.3 Chaperonopathies
Chaperonopathies are conditions caused by pathology of molecular chaperones, either
through inherited or acquired genetic mutation or post translational modifications (Macario and
Conway de Macario, 2019). These chaperone mutants can lead to overexpression,
underexpression, destabilization, or other changes that perturb the normal function of the
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chaperone, causing disease. Many different types of diseases can have pathological molecular
chaperone hallmarks, including congenital conditions (like EVEN-PLUS syndrome), many
neurodegenerative diseases (such as Parkinson’s disease with Lewy bodies), myopathies (like
Limb-Girdle Muscular Dystrophy type 1D), autoimmune disorders caused by chaperones
stimulating the immune system, and certain cancers (Macario and Conway de Macario, 2019).
EVEN-PLUS syndrome is a rare congenital condition characterized by multiple facial
and skeletal malformations (Royer-Bertrand et al., 2015). Currently five cases of this condition
have been studied and all five probands have mutations in HSPA9, a gene that encodes the
mitochondrial Hsp70 mHSP70/mortalin (Royer, Bertrand et al., 2015; Younger & Vetrini, et al.,
2020). In vitro studies of two of the mHSP70 mutations, R126W and Y128C, have revealed that
the mutations lead to decreased thermal stability, decreased ATP hydrolysis activity, and
increased aggregation propensity of mHSP70 (Moseng et al., 2020). This work shows that
dysfunction of a molecular chaperone can contribute to disease through multiple mechanisms.
It has been shown that many Hsps, including Hsp27, Hsp40, Hsp60, Hsp70, and Hsp90,
localize to Lewy bodies, indicating that molecular chaperones may be involved in Parkinson’s
disease progression (McLean et al., 2002; Uryu et al., 2006; Leverenz et al., 2007). Further
research in human cell line models, yeast, mice, and Drosophila melanogaster have shown that
overexpression of Hsp70 leads to improved outcomes, including reduction of oligomeric alphasynuclein and rescue of alpha-synuclein-induced cytotoxicity (Auluck et al., 2002; Klucken et
al., 2004; McLean et al., 2004; Flower et al., 2005; Luk et al., 2008; Outeiro et al., 2008).
Furthermore, induction of a dominant negative Hsp70 in drosophila melanogaster accelerated
alpha-synuclein toxicity (Auluck et al., 2002). These data show that, when overexpressed,
molecular chaperones can have a protective role in neurodegenerative conditions and that
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downregulation of some molecular chaperones may be involved in acceleration of Parkinson’s
disease.
Limb-Girdle Muscular Dystrophy type 1D (LGMDD1) is a dominantly inherited
degenerative muscular disease characterized by progressive weakness and wasting of the
proximal muscles surrounding the hips and shoulders (Straub et al., 2018; Zima et al., 2019). A
wide variety of mutations across multiple domains of an Hsp40 protein, DNAJB6, have been
notably associated with LGMDD1 (Harms et al., 2012; Sarparanta et al., 2012; Sato et al., 2013;
Couthouis et al., 2014; Suarez-Cedeno et al., 2014; Yabe et al., 2014; Nam et al., 2015; Palmio et
al., 2015; Ruggieri et al., 2015; Bohlega et al., 2018; Kim et al., 2018; Zima et al., 2019; Palmio
et al., 2020). Initially, mutations within the glycine/phenylalanine-rich (G/F) domain were
reported in multiple cases of LGMDD1, spanning many families and locations, including Asia,
Europe, North America, and Saudi Arabia. Several of these mutations have been introduced into
a homologous yeast protein, Sis1, and a Sis1-DNAJB6 construct, SDSS, and subsequently shown
to disrupt client processing in yeast (Figure 1.4B, C, and D) (Stein et al., 2014). These
experiments will be discussed more extensively later in this chapter and in chapter 3. More
recently, mutations associated with LGMDD1 were found in the J-domain of DNAJB6,
specifically in a section of the J-domain that shows close proximity to the G/F domain (Palmio et
al., 2020). In vitro cell culture experiments show that when two of these mutants, DNAJB6A50V and DNAJB6-E54A, are individually expressed the cells show impaired anti-aggregation
activity in the presence of either expanded polyglutamine Huntingtin protein or TDP-43 (Palmio,
2020). Studies conducted using the yeast homolog Sis1 show that expression of the A50V
mutation (Sis1-A49V in yeast) leads to impaired substrate refolding and alters client processing
by Sis1 (Pullen et al., 2020). Together, these results, show that G/F and J domain mutations can
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alter and disrupt client processing and indicate that alterations of protein domain interactions can
be detrimental to chaperone function and contribute to disease.
One example of a chaperone stimulating the immune response and causing an
autoimmune disorder is anti-Hsp60 activity in patients with atherosclerosis. Hsp60 is a
mitochondrial chaperonin that has a bacterial homolog, GroEL. Atherosclerosis is thought to be
initiated by T cells that recognize Hsp60 on endothelial cells, identifying Hsp60 as the
autoantigen for atherosclerosis (Jakic et al., 2019). Because Hsp60 has high homology with
GroEL it is thought that this autoimmunity can arise from high infection of bacteria. Indeed, high
infection rates have been correlated with incidences of atherosclerosis (Campbell and Rosenfeld,
2015). After infection with Chlamydia trachomatis, for example, Hsp60 antibodies were found at
high levels in patient sera, likely because the immune systems of these patients developed
antibodies against GroEL (Sanchez-Campillo et al., 1999). Because Hsp60 is present on the
plasma membrane of vascular endothelial cells to signal stress, T-cells immunized against Hsp60
recognize and attack these cells, leading to endothelial dysfunction and contributing to
atherosclerosis (Campbell and Rosenfeld, 2015). This example shows that chaperonopathies can
be acquired as a result of environmental stressors and complex extracellular processes.
Finally, evidence has been shown that members of the Hsp70 family are upregulated in
many types of cancer cells including prostate, breast, leukemia, lung, colon, and gastric cancers
(Kumar et al., 2016). It is known that Hsp70 expression is induced by cellular stress and that
overexpression of Hsp70 reduces apoptosis, so it is not surprising that overexpression of Hsp70s
could be beneficial to cancers. In fact, knockdown of Hsp70 has been shown to sensitize cancer
cells and reduce tumor size in animal models (Schmitt et al., 2006). The mechanisms by which
Hsp70s assist cancer growth and drug resistance are currently unclear; however current research
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suggests that certain cancers can be considered acquired chaperonapathies, as the overexpression
of Hsp70s heavily contribute to the growth and treatment-resistance of some cancer cells
(Macario and Conway de Macario, 2019).

1.3 Prions and Prion Propagation
1.3.1 Mammalian prions
Prions are proteins that misfold, self-template, and aggregate (Atkinson et al., 2016).
While functional prions exist, there are many prions that cause cellular dysfunction in neurons,
and neuronal cell death (Atkinson et al., 2016). Prion proteins have a natively-folded, soluble
state, but when misfolded, typically in a beta-sheet rich conformation, they template other
soluble prion protein molecules to misfold and form highly organized aggregate structures,
called amyloids. The mammalian prion protein (PrP) misfolds to cause the human diseases
Creutzfeldt-Jakob Disease (CJD), Gerstmann-Straussler-Scheinker disease (GSS), Familial Fatal
Insomnia (FFI), kuru, and variant CJD (vCJD) (Venneti, 2010). PrP aggregates also cause a wide
range of diseases in non-human mammals, including Scrapie in sheep and goats, Transmissible
Mink Encephalopathy, Chronic Wasting Disease in deer, and Bovine Spongiform
Encephalopathy in cattle (Marin-Moreno et al., 2017). The pathogenic form of PrP is known as
PrPSc, so named for Scrapie in sheep and goats (Prusiner, 1998). The soluble form of PrP is
known as PrPC and acts as a cell-surface glycoprotein (Sarnataro et al., 2017).

1.3.2 Yeast prions
A variety of prions also exist in yeast and fungi, in which they confer epigenetic
inheritance of certain traits to progeny (Shorter and Lindquist, 2005). Presently, nine amyloidbased prions have been discovered in Saccharomyces cerevisiae (Chernoff et al., 2020). This
variety represents a number of proteins with diverse cellular processes, different levels of
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expression in wild yeast and laboratory strains, and positive and negative biological effects as a
result of amyloid formation (Chernoff et al., 2020).

1.3.3 [PSI+] and [RNQ+]
[PSI+] is a yeast prion that has been shown to impart transient beneficial characteristics,
such as enhanced growth in adverse environments, that can be adopted as permanent traits
independent of [PSI+] status (True et al., 2004). Furthermore, it is known that environmental
stressors can induce [PSI+] formation (Tyedmers et al., 2008; Westergard and True, 2014).
Together these studies indicate that yeast prions can be induced by adverse events and utilized to
increase current and future survivability. [PSI+] is the prion form of the protein Sup35. Sup35 is
the yeast homolog of human eRF3 and, along with Sup45 (human eRF1), is involved in stop
codon recognition during translation termination. Because of this unique role in protein
translation, yeast have been genetically manipulated to develop a unique [PSI+]-dependent
colorimetric assay that will be discussed later in this chapter.
[RNQ+], another yeast prion, is known to be important for [PSI+] propagation (Derkatch
et al., 2004). Rnq1 protein, the role of which is unknown, misfolds and aggregates to form
[RNQ+]. [RNQ+] has been shown to template [PSI+] and greatly enhances [PSI+] formation
(Keefer et al., 2016). Furthermore, aggregation of ectopic huntingtin exon1 with an expanded
polyglutamine region is dependent on the presence [RNQ+] (Meriin et al., 2002).

1.3.4 Molecular chaperones required for prion propagation
Interestingly, the Hsp40 Sis1 is important for maintenance of both the [PSI+] and [RNQ+]
prions, though studies have shown that [RNQ+] is more drastically affected by reduction of Sis1
(Higurashi et al., 2008). It has been shown that Sis1 binds to Rnq1 in [RNQ+] cells and is
required for propagation of [RNQ+], making [RNQ+] propagation a potential readout for Sis1
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function (Higurashi et al., 2008). In sis1 cells, DNAJB1, the human homolog of Sis1 and potent
molecular chaperone, can compensate for Sis1 loss, further establishing the potential for [RNQ+]
propagation as an experimental model for studying Hsp40 activity (Lopez et al., 2003). While
the [PSI+] prion is not “cured” as quickly by Sis1 deletion or repression as [RNQ+], [PSI+]
propagation is greatly hindered by repression of Sis1 (Higurashi et al., 2008). In fact, upon Sis1
repression, [RNQ+] propagation ceases after 20 generations and [PSI+] propagation ceases only
after 80 generations (Higurashi et al., 2008).
Both [RNQ+] and [PSI+] require the activity of molecular chaperone Hsp104. Deletion of
HSP104 eliminates both [PSI+] and [RNQ+], however overexpression of HSP104 also eliminates
[PSI+], but does not affect [RNQ+] (Liebman and Chernoff, 2012). As described previously,
Hsp104 interacts with Hsp40 and Hsp70 to promote disaggregation of aggregate proteins. It is
thought that this disaggregase activity is required for virtually all yeast prion propagation
because it breaks large aggregates into smaller aggregates that can be passed on to daughter cells
without diluting prion units (Liebman and Chernoff, 2012). Less is known about the mechanism
by which Hsp104 overexpression eliminates [PSI+]. Microscopic assays with fluorescentlylabeled Sup35 show that upon Hsp104 overexpression reveal [PSI+] aggregates that are visible in
some cells and become unresolvable in other cells (Greene et al., 2020). Upon starvation stress
however, these aggregates reappear. It is unknown if this phenotype is due to Hsp104 completely
dismantling Sup35 aggregates into monomeric protein, or to Hsp104-mediated oligomerization
of aggregates such that they cannot be visualized through fluorescent microscopy. An aggregate
“trimming” role of Hsp104 has been proposed to explain this observation, in addition to its
already established severing activity (Shorter and Lindquist, 2004; Shorter and Lindquist, 2006),
however more evidence and investigation is needed to support this (Greene et al., 2020).
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1.3.5 Prion variants
Both [RNQ+] and [PSI+] prions can form different variants that have many distinct
phenotypes and are thought to result from discrete protein conformations (Huang et al., 2013;
Dergalev et al., 2019; Huang and King, 2020). These variants can be distinguished using
methods such as thermostability assays (Huang et al., 2013), semi-denaturing agarose gel
electrophoresis (SDD-AGE) (Huang et al., 2013; Huang and King, 2020), colorimetric assays
(Huang et al. 2013; Huang and King, 2020), structural analysis (Dergalev et al., 2019),
fluorescent microscopy (Huang et al., 2013; Huang and King, 2020) and, in the case of [RNQ+],
the ability to induce other prion formation (Huang et al. 2013). Known [RNQ+] variants are
single or multi-dot low, medium, high, and very high, so named for their appearance as one or
several puncta when evaluated by fluorescent microscopy (single or multi-dot) and their ability
to induce [PSI+] formation (low, medium, high, or very high) (Bradley et al., 2002; Sharma &
Liebman, 2013).
Known [PSI+] variants can be observed by a colorimetric assay that takes advantage of
the stop codon recognition property of Sup35 and is shown in Figure 1.2. In this assay, red yeast
colonies are populated by monomeric, or soluble, Sup35 and are [psi-] and white, light pink, and
dark pink colonies are populated by both monomeric and aggregated Sup35 and are [PSI+]
(Liebman and Chernoff, 2012). This change in color occurs because a premature stop codon has
been introduced in a gene (ADE1) in the adenine biosynthesis pathway. When Sup35 exists as a
monomer it participates in the recognition of this premature stop codon in the Ade1 gene (known
specifically as ade1-14), Ade1 is not produced, and the adenine biosynthesis pathway is
disrupted, which causes a red byproduct to accumulate in the cell (Liebman and Chernoff, 2012).
This is why [psi-] colonies appear red in color. Furthermore, because the adenine biosynthesis
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pathway is disrupted these cells cannot grow on media lacking adenine (Liebman and Chernoff,
2012). When Sup35 is aggregated in [PSI+] cells, the protein is titrated away from its role in
recognizing stop codons and there is readthrough of the premature stop codon in the ade1-14
allele, Ade1 is made, and the adenine biosynthesis pathway is restored (Liebman and Chernoff,
2012). These cells do not accumulate a red byproduct, so they appear white (or pink) and can
grow on media lacking adenine (Liebman and Chernoff, 2012). [PSI+] strains are separated
primarily by color from very weak to strong [PSI+]. Very weak [PSI+] corresponds to dark pink
colonies, weak [PSI+] are medium pink, medium [PSI+] are lighter pink, and strong [PSI+] are
pale pink or white in color.
[PSI+] variants can also be distinguished by mitotic stability, measured by the
frequency of [PSI+] loss, levels of monomeric Sup35, and the level of nonsense codon
suppression (Derkatch et al., 1996; Dergalev et al., 2019; Huang and King, 2020). It is known
that monomeric Sup35 and faithful translation termination rates are higher in weak [PSI+] and
that strong [PSI+] is more mitotically stable than weak [PSI+] (Derkatch et al., 1996; Uptain et
al., 2001). Furthermore, in vitro studies have shown that when prion formation is seeded by
strong [PSI+], prion fibers form more efficiently than when seeded by weak [PSI+] (Uptain et al.,
2001).

1.3.6 Saccharomyces cerevisiae as a model for Huntington’s disease
Not only is [RNQ+] required for other yeast prion formation, it is required for the
formation of mutant Huntingin protein aggregation in yeast (Meriin et al, 2002). Yeast present a
compelling model for studying amyloid diseases. As yeast prions are not cytotoxic when
expressed at homeostatic levels, they can be utilized to better understand the effects of chaperone
alteration on aggregate formation and propagation. Because yeast present a tractable genetic
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model, chaperone expression is easily altered and studied. Furthermore, the ability to
preferentially select yeast that have taken up a plasmid allows for the integration and study of
human aggregating proteins within wild type (WT) yeast cells, as well as strains that have been
genetically altered to variably express molecular chaperones.
A variety of neurodegenerative and amyloidogenic proteins have been introduced and
studied in yeast. These studies have identified new potential therapeutic targets and revealed
mechanisms by which human proteins cause toxicity (Di Gregorio and Duennwald, 2018).
Huntington’s Disease has been modeled in Saccharomyces cerevisiae with great success.
Huntington’s Disease is an autosomal dominant neurodegenerative disease that is caused by
expanded CAG repeats (>39) in the HTT gene (McColgan and Tabrizi, 2018). These repeats
result in an abnormally long stretch of glutamines in the huntingtin protein, which makes the
protein less stable, and, over time, more prone to aggregation. A common Huntington’s Disease
model in yeast is generated by the introduction of constructs expressing part of WT Huntingtin
(htt) exonI with 25 CAG repeats, resulting in 25 glutamines (25Q) or mutant Huntingtin (mhtt)
103 CAG repeats, resulting in 103 glutamines (103Q). Each construct is denoted as htt25Q (or
25Q htt exon I) and htt103Q (or 103Q htt exon I), respectively. Flanking regions of this core
protein have a profound effect on aggregation and toxicity and it has been shown that Nterminal-FLAG-tagged and C-terminal CFP-tagged htt103Q under the control of a Gal1
promoter is cytotoxic and forms aggregates when induced (Duennwald et al., 2006). This
construct and its non-cytotoxic 25Q counterpart are utilized in Chapter 2 of this dissertation.
Studies using these and similar constructs have revealed mechanistic insights into htt103Q
aggregation and toxicity. Cells expressing htt103Q were found to be defective in respiration,
which is caused by impairment in mitochondrial respiratory chain complex II and III activities,
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which are integral to ATP production (Solans et al., 2006). The same group of researchers found
that overexpression of Hap4, which participates in mitochondrial gene expression regulation,
suppresses PolyQ toxicity, likely through enhancing couple mitochondrial respiration (Ruetenik
et al., 2016). Moreover, it was shown that mutant huntingtin toxicity is achieved through
different mechanisms in various yeast strains, leading to the hypothesis that htt103Q could cause
toxicity through distinct mechanisms in neurons of varying brain compartments or cells in other
tissues (Serpionov et al., 2017). Duennwald and Lindquist used a yeast model to show that
htt103Q fragments entrap the proteins Np14, Ufd1, and p97, which causes a profound defect in
endoplasmic reticulum-associated degradation (ERAD) (2008). They also show that after only
eight hours of htt103Q induction both the profound defect in ERAD and upregulation of ER
stress proteins BiP, PDI, and CHOP can be detected (Duennwald and Lindquist, 2008). Lastly,
they show that the heat-shock response (HSR), which is normally activated by unfolded proteins
in the cytosol is unaffected by htt103Q aggregation (Duennwald and Lindquist, 2008).
Interestingly, molecular chaperones, such as Sis1 and TriC, have been implicated in prevention
of and the cellular response to expanded polyglutamine aggregation (Tam, et al., 2009; Klaips, et
al. 2020). Altogether, these studies show the rich potential of Saccharomyces cerevisiae as a
model for examining the mechanisms by with expanded polyglutamine aggregates and
discovering potential avenues for ameliorating the toxic effects of this aggregation.

1.4 The Nascent Polypeptide-Associated Complex
1.4.1 NAC subunits and co-translational protein folding
The Nascent Polypeptide-Associated Complex (NAC) is the first point of contact for
newly synthesized proteins as they exit the ribosome. The NAC is a heterodimeric complex and
its deletion causes embryonic lethality in multicellular eukaryotes (Deng and Behringer, 1995;
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Bloss et al., 2003). The heterodimeric structure is formed by the binding of an alpha subunit and
a beta subunit, known as NACA and BTF3 respectively in humans and Icd-2 and Icd-1 in C.
elegans (Arsenovic et al., 2012). These subunits form a beta-barrel structure through a conserved
NAC binding domain in each subunit consisting of 6 antiparallel beta-strands (Kogan et al,
2014). In Saccharomyces cerevisiae there is one alpha subunit, Egd2, and two beta subunits,
Egd1 and Btt1. Btt1 and Egd1 have 64.3% homology with stark differences in their C-terminal
regions and Btt1 arose from a yeast-specific genome duplication event (Ott et al, 2015). Egd1 is
present at 100x the concentration of Btt1 in the cell (Reimann et al., 1999). Both the beta and
alpha subunits reversibly bind the NAC to the ribosome in a one to one ratio, however it is
currently known that the beta subunit binds with multiple ribosomal proteins (Rpl31, Rpl25/35),
while the alpha subunit interacts with the ribosomal protein Rpl17 only (Pech et al., 2010). Both
the alpha and beta subunits bind nascent polypeptides as they exit the ribosome and it is currently
theorized that the NAC does this to prevent off pathway folding or interactions with other
proteins in the cytoplasm. All three NAC subunits in yeast have been shown to form homodimers
that associate with translating ribosomes, thus complicating and diversifying the system (Wang
et al., 2010; Del Alamo et al., 2011).
Analysis of NAC subunit specificity has shown that the Egd1-Egd2 NAC, Btt1-Egd2
NAC, and homodimers of each subunit have differing preferences for nascent polypeptides, the
diversity of which stretches to encompass almost every nascent polypeptide in the cell (del
Alamo et al, 2011). Microarray data of mRNA recovered from RNCs isolated by their
association with specific TAP-tagged chaperones shows that Btt1 preferentially binds to RNCs
translating shorter, more intrinsically disordered, less hydrophobic proteins with higher
translation rates (del Alamo et al, 2011). Conversely, Egd1 binds to RNCs translating longer, less
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intrinsically disordered, more hydrophobic proteins with slower translation rates (del Alamo et
al., 2011). Egd2 alone was associated with RNCs enriched with secretory pathway proteins,
notably proteins targeted to the ER (del Alamo et al, 2011). This further suggests that Egd2 can
function as a homodimer.

1.4.2 NAC interactions with SRP and the ER
The NAC is also involved in ribosome shuttling to the endoplasmic reticulum (ER) and
mitochondria (Gamerdinger et al., 2015; Zhang et al., 2012; Ponce-Rojas et al., 2017). In
Saccharomyces cerevisiae, evidence suggests that the NAC modulates activity of the signal
recognition particle (SRP) and ribosomal ER-targeting in a variety of ways. The SRP is a
ribonucleoprotein that recognizes and binds to signal sequences of nascent proteins and targets
those proteins and the ribosome translating them to the ER. The NAC is required for SRP
recruitment to ribosomes translating proteins with signal sequences while the signal sequence is
still in the ribosome exit tunnel (Zhang et al., 2012). The NAC is able to bind to these signal
sequences as well, and both the NAC and SRP are able to bind to the ribosome and nascent
polypeptides simultaneously (Zhang et al., 2012). Lastly, this work showed that even when the
ribosome has docked to the ER membrane the NAC stays bound to the ribosome (Zhang et al,
2012). It is hypothesized that this allows the NAC to bind to nascent polypeptides and protect the
exposed sequence from inappropriate or off-pathway interactions during recruitment to the ER
membrane and during translocation of the protein into the ER. In C. elegans, beta-nac depletion
has been shown to increase ribosome localization to the ER membrane, suggesting NAC is a
negative regulator of ribosomal binding to the ER (Gamerdinger et al, 2015). Further work has
shown that NAC regulates SRP-independent binding of the ribosome to the ER and induces
ribosome release from the ER after translation termination (Gamerdinger et al, 2015).
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Furthermore, NAC overexpression reduces SRP-dependent binding to the ER (Gamerdinger et
al, 2015). Altogether, this research shows that NAC is a potent regulator of ribosome targeting
and binding to the ER, and that the activity of the complex heavily modulates SRP-dependent
ribosome targeting to the ER (Gamerdinger et al, 2015). More recently, detailed in vitro
examination of the NAC and SRP interaction demonstrated that even at small concentrations the
NAC is capable of reducing SRP interaction with SRP receptor in the presence of a nonfunctional signal sequence, while the NAC has no effect on SRP interaction with SRP receptor in
the presence of a functional signal sequence (Hsieh et al, 2020). This work confirms that NAC
and SRP co-bind to ribosomes and, through single molecule FRET and TIRF microscopy, that
the NAC induces conformational changes in SRP, which regulates SRP and SRP receptor
interaction (Hsieh et al, 2020). Moreover, the NAC was shown to greatly reduce SRP association
with the ribosome until the nascent polypeptide chain has grown long enough to exit the
ribosome, thus delaying targeting of the ribosome to the ER until the signal sequence can be
recognized by SRP (Hsieh et al, 2020).

1.4.3 NAC interactions with the mitochondria
Egd2 (NAC α subunit) has been implicated in yeast ribosome targeting to the
mitochondria for over twenty years (George et al, 1998). Continued research implicated NAC in
ribosomal association with the mitochondrial surface (as deletion of the NAC resulted in fewer
ribosomes present on mitochondria) and as a stimulator of protein import into the mitochondria
(George et al, 2002; Funfschilling and Rospert, 1999). More recent work in Saccharomyces
cerevisiae has shown that the NAC, specifically the Egd2 and Btt1 heterodimer, physically
interacts with Sam37 and they work together to navigate the early stages of mitochondrial
protein import. (Ponce-Rojas et al, 2017). Sam37 is a subunit of the sorting and assembly
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machinery (SAM) complex in the mitochondria. Sam37 contributes to the stability of the
complex as well as the physical interaction between the translocase of the outer membrane
(TOM) and SAM complexes. Furthermore, it has been shown that the NAC interacts with the
mitochondrial receptor OM14 (Lesnik et al, 2014). These findings indicate that the NAC is
heavily involved in many steps required for co-translational mitochondrial protein targeting and
import. Based on this conclusion it is unsurprising that, upon analysis of mRNAs present in the
ER lumen of C. elegans depleted of beta-NAC, it was found that mitochondrial proteins were
strongly mistargeted to the ER, along with cytosolic and nuclear proteins (Gamerdinger et al,
2015).

1.4.4 Effects of NAC overexpression
Work in C. elegans has shown that overexpression of the NAC over a particular threshold
is lethal and that moderate (2- to 3-fold) overexpression of the complex results in developmental
delays (Gamerdinger et al, 2015). Somewhat surprisingly, the same body of work reported that
alpha and beta nac depletion separately and in combination reduces lifespan and that
combinatorial nac depletion induces endoplasmic reticulum and mitochondrial stress in wild type
animals (Gamerdinger et al, 2015). Beta-nac suppression specifically leads to high levels of ER
stress reporter induction (Gamerdinger et al, 2015). Potentially conflicting data collected in
Saccharomyces cerevisiae indicates that nac deletion did not result in transcriptional activation
of the unfolded protein response (UPR) (del Alamo et al, 2011). These data suggest the NAC is
vital for development and global homeostasis, however its importance in specific cell-type or
organ system homeostasis and the potential benefits from overexpressing or suppressing the
NAC remain unknown.

21

Overexpression of the N-terminus of the beta-NAC subunit has been shown to reduce
poly-glutamine aggregation in C. elegans (Shen et al., 2019). The work by Shen at al. shows that
the positively charged N-terminus of beta-NAC delays poly-glutamine aggregation
independently of its previously defined ribosome-associated roles.

1.4.5 Effects of NAC deletion
While NAC deletion in higher order eukaryotes has been shown to cause embryonic
lethality, deletion of the NAC and NAC subunits has little to no effect on growth in
Saccharomyces cerevisiae. In fact, NAC deletion and disruption is beneficial to in S. cerevisiae
in the presence of aggregating prion protein. Previously, a screen in the True lab was conducted
to find cellular modifications that rescued [PSI+]-induced cytotoxicity. [PSI+] formation does not
normally induce cytotoxicity, however when the aggregating protein (Sup35) is grossly
overexpressed in [PSI+] cells, cell death occurs. This screen sought to identify gene disruptions
that abolished cytotoxicity without curing the prion status of the cells, thereby discovering
potential therapeutic targets to treat a wider variety of protein misfolding conditions. One gene
disruption discovered in this screen was that of egd1 (Figure 1.3A). This result was highly
surprising, as Egd1 is an essential protein-folding chaperone involved in multiple cellular
processes. Further work showed that two NAC deletion strains in particular, egd1egd2 and
egd1btt1, robustly rescued cell viability in [PSI+] cells overexpressing SUP35 (Figure 1.3A)
(Keefer & True, 2016). While deletion of the NAC subunits did not cure the [PSI+] prion,
aggregate formation and distribution in the egd1egd2 strain was altered as compared to WT
and other NAC deletion strains (Figure 1.3B) (Keefer & True, 2016). It was hypothesized that
deletion of the NAC subunits in the egd1egd2 and egd1btt1 strains delayed the joining of
newly synthesized Sup35 to preexisting prion aggregates, based on data showing delayed
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detection of de novo expressed Sup35 in the pelleted fraction of [PSI+] cell lysates of the
egd1egd2 and egd1btt1 strains (Figure 1.3C) (Keefer & True, 2016). It was determined
that this change in the egd1egd2 strain could be due to changes in chaperone balance in the
strain. Analysis of Ssb localization showed that Ssb was heavily localized to polysomes and
nearly absent from Sup35 aggregates in [PSI+] cells, as compared to a more moderate
distribution of Ssb to both polysomes and Sup35 aggregates in WT cells (Figure 1.3D) (Keefer
&True, 2016). Importantly, while the egd1btt1 strain did not induce changes in Ssb
localization to polysomes compared to WT, the strain did have a marked decrease in Ssb
localization to Sup35 aggregates in [PSI+] cells, similar to the egd1egd2 strain (Keefer &
True, 2016). Lastly, this work showed robust resistance to general protein misfolding cytoxicity
induced by canavanine treatment in a variety of NAC deletion strains (Figure 1.3E) (Keefer &
True, 2016). Overall, this work revealed the NAC as a potential target for disruption in the
treatment of protein misfolding diseases.

1.5 Limb-Girdle Muscular Dystrophy Type 1D (LGMDD1)
1.5.1 Limb-Girdle Muscular Dystrophies
As stated previously in this chapter, Limb-Girdle Muscular Dystrophy (LGMD) is a
group of muscular weakness and wasting disorders that are characterized by shoulder and pelvic
girdle onset (Liewluck and Milone, 2018). LGMDs are separated into two categories, LGMD
Type 1 (LGMD1) and LGMD Type 2 (LGMD2). Within these types are subtypes 1A-1H and
2A-2Z, respectively (Liewluck and Milone, 2018). LGMD1 and LGMD2 differ in a number of
features, including that LGMD1 is an autosomal dominant condition while LGMD2 is autosomal
recessive and the LGMD subtypes are separated by known causative genes.
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1.5.2 J-Proteins
LGMD type 1D (LGMDD1) is caused by mutations in the DNAJB6 gene. DNAJB6 is an
Hsp40, or J-protein, involved in protein folding in conjunction with Hsp70s. Mutations in
DNAJB6 associated with LGMDD1 have been found in the G/F and J domains of the protein
(Harms et al., 2012; Sarparanta et al., 2012; Sato et al., 2013; Couthouis et al., 2014; SuarezCedeno et al., 2014; Yabe et al., 2014; Nam et al., 2015; Palmio et al., 2015; Ruggieri et al.,
2015; Bohlega et al., 2018; Kim et al., 2018; Zima et al., 2019; Palmio et al., 2020).
Hsp40s/DNAJs/J-proteins are an expansive group of proteins that share a characteristic Jdomain. This domain is located at the N-terminus, 70 amino acids in length, and, most
importantly, stimulates the Hsp70 ATPase activity. There is a conserved HPD-motif (histidine,
proline, aspartic acid) within the J-domain that is crucial for stimulating the ATPase activity of
Hsp70 (Tsai and Douglas, 1996). This motif is at position 31-33 in the amino acid sequence of
DNAJB6. There are three DNAJ protein subtypes, I or A, II or B, and III or C. All three subtypes
contain the conserved J-domain, though the J-domain is not necessarily located at the N-terminus
in subtype III (or C) (Kampinga and Craig, 2010). Both subtypes I (or A) and II (or B) contain a
conserved glycine/phenylalanine (G/F)-rich domain, the function of which is unclear, and a Cterminal region that identify and bind to client proteins (Liewluck and Milone, 2018). Lastly,
subtype I (or A) contains a cysteine-rich reason bordered by the G/F-rich domain and the Cterminal substrate binding region.

1.5.3 DNAJB6 structure and expression
DNAJB6 is a Type II (or B) protein and therefore contains a J-domain with the conserved
HPD motif, G/F domain, and a C terminal domain. DNAJB6 exists within the cell in two
isoforms, DNAJB6a and DNAJB6b, created by alternative splicing. The main difference
between these two isoforms is the length of the C-terminal domain. DNAJB6a is the longer
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isoform and has a nuclear localization signal, while DNAJB6b is shorter and has been shown to
have cytosolic and nuclear localization (Bengoechea et al., 2015). DNAJB6 is expressed in most
human tissues; interestingly, however, DNAJB6 expression is relatively low in mouse and
human skeletal muscle (Ding et al., 2016).

1.5.4 DNAJB6 mutations in LGMDD1
Mutations in the G/F and J domains of DNAJB6 have been found in patients with
LGMDD1. Discovery of new mutations is ongoing, as are studies to uncover the mechanisms by
which these mutations modulate DNAJB6 activity. Many of these mutations have been shown to
reduce the anti-aggregation activity of DNAJB6 (Sarparanta et al., 2012; Palmio et al., 2018;
Bengoechea et al., 2015; Sarparanta et al., 2020; Stein et al., 2014, Pullen et al., 2020).
Unfortunately, there is no known client of DNAJB6 in humans, making it difficult to directly
study the functional changes caused by these mutations. Sis1 is a Type II HSP40 in yeast that
interacts with the HSP70 Ssa1 and has known client proteins, which include Rnq1 and Sup35. As
stated previously, Sis1 is required for propagation of both [RNQ+] and [PSI+] prions. Because
Sis1 has homology with DNAJB6 and another human J-protein, DNAJB1, this system has been
exploited repeatedly to better understand the effect of LGMDD1 mutations. These studies have
shown that multiple G/F and J domain mutations alter prion and non-prion client processing
(Stein et al., 2014; Pullen et al., 2020; Bengoechea et al., 2020). Because DNAJB1 is more
closely homologous to DNAJB6 and can compensate for the cytotoxic loss of Sis1, Stein et al.
introduced the disease related DNAJB6 mutations F89I, F93L, and P96R into DNAJB1 (2014).
They then introduced these constructs into a yeast sis1 [RNQ+] model. They found that WT
Sis1 and WT DNAJB1 were able to maintain the propagation of the [RNQ+] prion, but that cells
expressing the DNAJB1 proteins containing the F93L and P96R mutations displayed a
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significant reduction in [RNQ+] propagation (Stein et al., 2014). Expression of the DNAJB1
protein with the F89I mutation (DNAJB1-F90I) proved cytotoxic, so they were unable to access
[RNQ+] in these cells (Figure 1.4A) (Stein et al., 2014). While unfortunate for continued
experimentation, this result allowed for a unique opportunity to probe for intragenic second-site
suppressors of this strong phenotype.
Because the DNAJB6-F89I mutation showed the strongest phenotype, Stein et al. wanted
to further investigate its effect on [RNQ+] and [PSI+] propagation. To do this they created a
chimeric protein that contained the G/F domain of DNAJB6 and the J, G/M, and CTD of Sis1
(Figure 1.4B) (Stein et al., 2014). This protein was named SDSS, which denotes the origin of
each domain. It was reasoned that SDSS would combine the disease relevant domain of
DNAJB6 and the prion propagation and viability roles of Sis1. Indeed, sis1 cells expressing
SDSS-F89I were viable, and while WT SDSS, SDSS-F93L, and SDSS-P96R were able to
maintain prion propagation of single dot medium [RNQ+], weak [PSI+], and a lab-created [PSI+]
strain known as Sc37, SDSS-F89I expressing cells were cured of prions (Figure 1.4C and D)
(Stein et al. 2014). Interestingly, this loss of prion propagation was not seen in cells expressing
the SDSS mutants and containing multi-dot high [RNQ+], strong [PSI+], or a lab-created [PSI+]
strain known as Sc4 (Figure 1.4C and D) (Stein et al. 2014). This result shows that these mutant
chaperones may be able to interact with and influence some protein conformers but not others.
The clear viability phenotype in DNAJB1 with the F89I mutation combined with the clear
propagation of particular prion strains defect phenotype in SDSS-F89I present an intriguing
system for study, which will be discussed in Chapter 3.
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1.5.5 Intragenic second-site suppressors
Intragenic second-site suppressors are secondary mutations that partially or completely
revert a mutant protein back to WT function. Discovery of second-site suppressors often leads to
new insights in protein function, domain interactions, and potential therapeutic avenues. As the
role of the G/F domain remains unclear, second-site suppressors of G/F domain mutants could
advance our understanding of G/F domain function and its potential interaction with other
DNAJB6 domains. Investigation into the effects of second site suppressors of the DNAJB6 F89I
mutation will be further discussed in Chapter 3 of this work.

1.6 Summary and Significance
Protein folding is critical for cell survival and as such the cell has developed many ways
to improve and enhance the protein folding environment. Molecular chaperones that engage in
co- and post-translational protein folding are factors that often improve protein folding and
promote homeostasis and proteostasis. Even with this network of molecular chaperones there are
proteins that misfold and aggregate, often harming the cellular environment and causing
irreversible damage to the organism. Outstanding questions in this field include identifying how
modulation of molecular chaperones can affect the protein folding environment and how
perturbations in molecular chaperone activity can be addressed. This dissertation attempts to
address these questions.
Chapter two of this document investigates the NAC and how deletion of particular NAC
subunits delays and alters protein aggregation and cytotoxicity of human disease-causing
proteins. It also reveals changes in yeast prion aggregation and induction as a result of NAC
subunit deletion. This work illuminates chaperone complex modulation as a potential suppressor
of neurodegenerative disease or other protein conformational disorders. Chapter three identifies
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and evaluates second-site suppressors of DNAJB6 mutations. These studies were conducted in
the DNAJB6 and Sis1 chimeric protein SDSS and the yeast Hsp40 Sis1. Two second site
suppressors are shown to rescue the client-associated activity of SDSS and Sis1 that are
disrupted by disease associated mutations. These data show the potential of second-site
suppressors as potent therapies for rescuing protein activity and open new avenues of research
into the mechanism by which they rescue SDSS and Sis1 activity. Overall, this work addresses
important areas of molecular chaperone modulation and activity and may serve to inform further
research into reduction and prevention of protein misfolding-induced cellular toxicity.
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1.7 Figures

Figure 1.1 Molecular chaperones effects on protein folding. Illustrations adapted (Hartl et al.,
2011; Preissler and Deuerling, 2012); (A) Proteins can adopt innumerable folding conformations
characterized by various levels of free energy and intra- or inter-molecular contacts. Proteins
sample various folds as they attempt to fold in the lower free energy, native state. Conversely,
proteins may, through intermolecular interactions, form amorphous aggregates, oligomers, or
amyloid fibrils. Molecular chaperones are involved in promoting native state folding
conformations and disrupting and reducing amorphous aggregate, oligomer, and amyloid fibril
conformations. (B) Molecular chaperones exist as a network of co- and post-translational protein
interactors. Bound to the ribosome and the first point of nascent protein contact is the NAC
(nascent polypeptide-associated complex). The RAC (ribosome associated complex) consists of
Zuo, which binds to the ribosome, Ssz, and Ssb, which interacts with nascent polypeptides.
Prefoldin, Ssa, and Ydj or Sis1 interact with and assist in folding proteins either after they exit
the ribosome, as they exist in the cytosol as folding intermediates, or before or after interactions
with TRiC/CCT. Each of these interactions promotes folding of the protein to its native state.
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Figure 1.2 [PSI+] colorimetric phenotypes. Illustration adapted (True, 2003; Keefer, 2017). In
the absence of prion Sup35 participates in stop codon recognition of the premature stop codon in
ade1-14. There is faithful termination of translation, Ade1 is not made, a red byproduct builds up
in the cell, and the cells cannot grow on media lacking adenine. When prions are present Sup35
is titrated away from stop codon recognition, there is nonsense suppression of the premature stop
codon, Ade1 is made, there is no build-up of red byproduct, and the cells can grow on media
lacking adenine. Different prion variants are associated with various levels of nonsense
suppression, leading to variations on color. The weak [PSI+] prion variant leads to lower levels
of nonsense suppression, some buildup of red byproduct, making colonies appear pink in color.
The strong [PSI+] variant causes higher levels of nonsense suppression and very little red
byproduct, resulting in a white colony phenotype.
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Figure 1.3 NAC deletion effects on [PSI+] formation, chaperone localization, and protein
folding environment. Figure adapted from Keefer and True, 2016. (A) NAC subunits were
deleted in [PSI+] cells and SUP35 overexpression was induced by spotting on selective media
containing CuSO4. The original screen Egd1 disruption is represented as egd1t. (B) WT and
NAC deletion strains were transformed with a copper-inducible plasmid expressing GFP-tagged
SUP35, grown overnight in selective media, induced by CuSO4, and imaged. (C) [PSI+] WT and
NAC deletion strains were grown overnight in selective media and expression of GFP-tagged
SUP35 was induced by CuSO4. GFP-tagged Sup35 was detected by western blot. (D) Ssb levels
in WT and NAC deletion strains were detected in monosome and polysome fractions by western
blot and are represented as ratios of Ssb expression in polysome relative to monosome. (E) WT
and NAC deletion strains were spotted on canavanine containing media to measure viability
during global protein misfolding stress.
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Figure 1.4 Disease-associated mutations in DNAJB6 cause client processing disruptions in
yeast. Figure adapted from Stein et al., 2014. (A) Homologous mutations to DNAJB6-F89I,
DNAJB6-F93L, and DNAJB6-P96R were introduced in DNAJB1. Yeast expressing these
mutant proteins and DNAJB1-WT were spotted to measure viability in the presence and absence
of Sis1. (B) Diagram showing the construction of Sis1-DNAJB6 chimeric protein SDSS. (C) WT
SDSS and SDSS mutants SDSS-F89I, SDSS-F93L, and SDSS-P96R were expressed in sis1
[rnq-], single dot medium [RNQ+], and multidot high [RNQ+] strains. Each strain expressed a
copper-inducible Rnq1-GFP as well and prion aggregation was evaluated via fluorescent
microscopy. (D) WT SDSS and SDSS mutants SDSS-F89I, SDSS-F93L, and SDSS-P96R were
expressed in sis1 [psi-], Sc37, Sc4, weak [PSI+], and strong [PSI+] strains. Strains were spotted
on rich media and evaluated for prion propagation by color.
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Chapter 2: Disruption of the Nascent
Polypeptide-Associated Complex Leads to
Reduced Polyglutamine Aggregation and
Toxicity

Leeran B. Dublin and Heather L. True

This chapter is in preparation for submission to a peer-reviewed journal.
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2.1 Abstract
The nascent polypeptide-associate complex (NAC) is a heterodimeric chaperone complex
that binds near the ribosome exit tunnel and is the first point of chaperone contact for newly
synthesized proteins. Deletion of the NAC induces embryonic lethality in many multi-cellular
organisms. Previous work has shown deletion of the NAC rescues cells from prion-induced
cytotoxicity. This counterintuitive result led us to hypothesize that NAC disruption would
improve viability in cells expressing human misfolding proteins. Here, we show that NAC
disruption not only improves viability in cells expressing alpha-synuclein and expanded
polyglutamine, but also leads to delayed and reduced aggregation of expanded polyglutamine
and changes in polyglutamine aggregate morphology. Moreover, we show that NAC disruption
leads to changes in de novo yeast prion induction. These results indicate that the NAC plays a
critical role in aggregate organization and has potential as a therapeutic target in
neurodegenerative disorders.

2.2 Introduction
Protein folding is vital for cell survival and maintaining cellular homeostasis. Some
proteins have amyloidogenic amino acid regions, which make them prone to misfolding and
aggregation, causing disease (Dobson, 2017). For example, Huntington’s Disease is caused by
elongated repeats of glutamine (polyQ) in the Huntingtin protein that lead to misfolding and
aggregation of the protein (Huang et al., 1998). The accumulation of these Huntingtin aggregates
in neurons entangles cellular resources and alters cellular processes, causing stress and eventual
cell death (Ravikumar et al., 2004, Koga et al., 2011, Ashkenazi et al., 2017, Vidal et al., 2012,
Lajoie and Snapp, 2012, Duennwald and Lindquist, 2008). Currently there are no therapies
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available for Huntington’s Disease and the process by which Huntingtin protein aggregates and
causes disease is not fully understood. Many studies on the effects of the expanded polyQ region
of Huntingtin protein (htt103Q) have been conducted in yeast models, showing that
polyglutamine toxicity disrupts ER stress responses, such as ER-associated degradation (ERAD)
(Duennwald and Lindquist, 2008).
Molecular chaperones operate as a vast and complex network, assisting in co- and posttranslational protein folding. Furthermore, molecular chaperones are known to assist in ribosome
shuttling to the endoplasmic reticulum and mitochondria by recognizing signal sequences on
nascent polypeptides (Zhang et al., 2012; Gamerdinger et al., 2015; Ponce-Rojas et al., 2017).
Many molecular chaperones are required for cellular growth and deleting these chaperones
results in cytotoxicity (Deng and Behringer, 1995; Barrott and Haystead, 2013; Helary et al.,
2019).
Surprisingly, past research has shown that deleting portions of a co-translational
molecular chaperone complex, the nascent polypeptide-associated complex (NAC), rescues yeast
prion induced cytotoxicity by altering the balance and localization of other molecular chaperones
(Keefer and True, 2016). The NAC is highly conserved and deletion of the complex is
embryonically lethal in many multicellular organisms (Deng and Behringer, 1995; Bloss et al.,
2003). The NAC is comprised of two classes of subunits known as alpha (α) and beta (β). Egd2
is the α subunit, while in yeast there are two β subunits, Egd1 and Btt1. Btt1 arose in yeast after a
genome duplication event, is known as the β’ subunit, and is 100 fold less concentrated in the
cell than Egd1. The NAC is most prominently present in the cell as a heterodimer of one α
subunit and one β subunit (Reimann et al., 1999; Del Alamo, et al., 2011). The β subunit
reversibly binds the complex to the ribosome in a one to one ratio near the ribosomal exit tunnel
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(Pech et al., 2010). Both the α and β subunits are the first point of contact for nascent
polypeptides within the exit tunnel and as they emerge from the ribosome (Gamerdinger et al.,
2019). The NAC also assists in the recognition of peptide signals and shuttling the ribosome to
the ER and mitochondria (Zhang et al., 2012; Gamerdinger et al., 2015; Ponce-Rojas et al.,
2017). Our group previously showed that partial deletion of the NAC rescued cytotoxicity in a
yeast prion model (Keefer and True, 2016). Work from other groups has shown that
overexpression of the NAC prevents aggregation by other misfolding proteins in yeast and other
organisms (Gamerdinger et al., 2015; Shen et al., 2019). Because of this work we wanted to
evaluate NAC modulation effects on human misfolding protein-induced cytotoxicity in yeast
cells.
Herein, we report that partial deletion of the NAC improves cellular growth in yeast
expressing a toxic expanded polyQ protein and reduces aggregation of polyglutamine. We also
show that partial deletion of the NAC reduces induction of certain yeast prion strains. These
results identify the NAC as a potential therapeutic target to reduce amyloidogenic protein
aggregation and further elucidate the mechanism by which NAC disruption improves the cellular
environment in the face of protein misfolding stress.

2.3 Results
2.3.1 NAC modulation effects on yeast expressing human misfolding proteins
We set out to investigate the ability of NAC modulation to improve viability in yeast
cells expressing human misfolding proteins. Previously, we have shown that NAC deletion
rescued prion-induced cytotoxicity, while others have shown that NAC overexpression delayed
protein aggregation (Keefer and True, 2016, Shen et al., 2019). Based on this work, we
hypothesized that modulating NAC subunit expression would rescue toxicity induced by human
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misfolding proteins. To test this hypothesis, we expressed multiple disease-causing human
misfolding proteins in the NAC deletion strains as well as WT yeast strains overexpressing NAC
subunits. We expressed two galactose-inducible partial huntingtin proteins, htt exon1 103Q and
htt exon1 25Q, as well as multiple galactose-inducible alpha-synuclein proteins, including wild
type and two disease-causing mutants (A30P and A53T) in a complete set of NAC deletion
strains and a WT strain. We spotted the egd1btt1, egd1egd2, nac, and WT transformants
on selective media containing glucose or galactose to evaluate toxicity induced by these alphasynuclein proteins (Figure 2.1A) and expanded polyglutamine (Figure 2.1B). We also
transformed a WT 74-D694 yeast strain with plasmids expressing NAC β-subunit Egd1 or NAC
α-subunit Egd2. We then transformed these strains with a plasmid expressing htt exon1 103Q or
an empty vector and spotted them to evaluate toxicity (Figure 2.1C). We were surprised to see
partial rescue of htt exon1 103Q toxicity in the egd1btt1 and egd1egd2 strains but not in
strains overexpressing Egd1 or Egd2. Other work has shown that overexpression of the NAC α
and β subunits suppressed expanded polyglutamine aggregation in C. elegans (Shen et al., 2019).
Interestingly, we also saw improved viability in the egd1egd2 and nac strains expressing
alpha-synuclein WT and disease-causing mutant constructs when compared to WT expressing
the same constructs (Figure 2.1A).

2.3.2 NAC disruption delays and reduces polyglutamine aggregation
Intrigued by these results, we investigated aggregation of htt exon1 103Q. While the
exact mechanism by which polyQ-expanded htt exonI causes toxicity is unknown, we know the
aggregation of polyQ is a contributing factor and marker of toxicity (McColgan and Tabrizi,
2018). To visualize htt exon1 103Q aggregation in egd1btt1 and egd1egd2 we induced
expression of the protein for 6 and 20 hours using a galactose inducible promoter. We then
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conducted microscopy and visualized the CFP-tagged htt exon1 103Q protein. We saw
significantly reduced aggregation in the egd1btt1 strain as compared to WT and egd1egd2
at both 6 and 20 hours of induction (Figure 2.2A). WT cells expressing htt exon1 103Q for 6
hours showed that an average of 37% cells contained aggregates while only 4.5% of the
egd1btt1 cells contained aggregates (Figure 2.2B). Even after inducing expression of htt
exon1 103Q for 20 hours, 41% WT cells contained aggregates while 13% of the egd1btt1
cells contained aggregates (Figure 2.2C).

2.3.3 NAC disruption changes polyglutamine aggregate distribution
Interestingly, we saw morphological differences between the htt exon1 103Q aggregates
present in the mutant strains as compared to the aggregates in wild type cells. To quantify
aggregate phenotype, we evaluated each cell expressing htt exon1 103Q and ranked them as 0-3
depending on the number of aggregates present in the cell (Figure 2.2D). These analyses were of
keen interest, as many groups have hypothesized and shown that soluble polyglutamine
oligomers are cytotoxic, while large insoluble, polyglutamine aggregate structures may pose less
risk to cellular homeostasis (Takahashi et al., 2008, Lajoie and Snapp, 2010, Lajoie and Snapp,
2013, Leitman et al., 2013). At 6 hours htt exon1 103Q induction, the aggregate populations in
WT and egd1btt1 aggregate populations were similar, as cells containing one aggregate
comprise about half of the aggregate population in both strains (Figure 2.2E). However, cells
containing three or more aggregates appear in 49% of cells with aggregates in the egd1egd2
strain at the 6 hour induction timepoint (Figure 2.2E). At 20 hours htt exon1 103Q induction,
aggregate populations observed in WT and egd1egd2 are similar (cells with one aggregate:
42% and 40%, two aggregates: 18% and 23%, and three or more aggregates: 39% and 37%)
(Figure 2.2E). Conversely, the most abundant aggregate population in the egd1btt1 strain after
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20 hours induction is one aggregate, which make up 60% of the aggregate population in
egd1btt1 cells (Figure 2.2E).

2.3.4 NAC disruption-induced reduction of polyglutamine aggregation is not
caused by reduced polyglutamine expression
We considered the possibility that the reduction of htt exon1 103Q aggregation in
egd1btt1 cells could be caused by reduced expression of htt exon1 103Q, as reduced
polyglutamine expression has been shown to reduce and reverse polyglutamine aggregate
formation (Yamamoto et al., 2000, Becanovic et al., 2015, Yang et al., 2016). To determine htt
exon1 103Q expression we performed western blots for the FLAG-tag attached to the Nterminus of the htt exon1 25Q and htt exon1 103Q proteins induced in the NAC deletion strains
for 6 hours. We saw no significant difference between htt exon1 103Q expression in WT and the
egd1btt1 strain at 6 hours induction (Figure 2.3A). We also detected htt exon1 103Q
aggregates after 6 and 20 hour induction in WT, egd1btt1, egd1egd2, and nac strains by
filter trap assay. Filter trap assays allow for the visualization and semi-quantification of large
protein aggregates, as these aggregates, unlike monomeric proteins, are unable to pass through
cellulose acetate membranes (Duennwald, 2013). We expected to see a reduction of aggregated
htt exon1 103Q by filter trap assay in the egd1btt1 strain compared to WT at both 6 and 20
hours of induction. We saw this result at the 6-hour time point (Figure 2.3B), but did not at the
20-hour time point (data not shown). Quantification of aggregated htt exon1 103Q signal
intensity showed a 53% percent reduction in the egd1btt1 strain compared to WT after 6
hours induction (Figure 2.3C).
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2.3.5 NAC disruption alters [PSI+] variant induction
We wanted to delve deeper into the change in aggregate morphology we saw with
microscopy. We utilized the well-characterized [PSI+] prion model in yeast, as de novo [PSI+]
strain induction can be used to better evaluate aggregate morphological differences as a result of
chaperone deletion. Furthermore, we wanted to investigate whether NAC disruption would
change aggregation morphology of another protein (Sup35) compared to WT. Saccharomyces
cerevisiae harbor a wide array of prions, which are normally non-cytotoxic. Non-cytotoxic
prions have potential as reporters for cellular protein folding environmental conditions. One
prion, [PSI+], has been used to develop a colorimetric assay that allows for the evaluation of
prion induction and prion strain determination.
Like polyglutamine, proteins that misfold to form prions can fold and aggregate in
different conformations, creating different prion strains. These strains can be differentiated by a
myriad of assays and, in the yeast [PSI+] prion system, by colony color. Sup35 is a protein
involved in stop codon recognition with Sup45. Sup35 misfolds and aggregates to form the yeast
prion [PSI+]. The 74-D694 yeast strain contains the ade1-14 allele. ADE1 encodes a protein that
is involved in the adenine biogenesis pathway, and ade1-14 contains a premature stop codon.
When Sup35 is natively folded the premature stop codon in ade1-14 is recognized and adenine
biosynthesis is interrupted. This results in the accumulation of a red byproduct in cells and
results in their inability to grow on media lacking adenine. When Sup35 misfolds and aggregates
there is readthrough of the premature stop codon in ade1-14, resulting in completion of the
adenine biogenesis pathway, no accumulation of red pigment in yeast cells, and colony growth
on media lacking adenine. [PSI+] prion strains include very weak, weak, medium, and strong
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[PSI+] and each strain can be recognized by the accumulation of pigment in yeast colonies,
ranging from [psi-] cells appearing red and strong [PSI+] cells appearing very light or pale pink.
Given the observed changes in htt exon1 103Q aggregate morphology, we hypothesized
that loss of the NAC would cause changes in the distribution of de novo [PSI+] prion strains
when compared to de novo [PSI+] prion strains induced in WT yeast. In order to induce prion
formation we expressed a Sup35 plasmid in WT and the NAC deletion strains (nac,
egd1egd2, and egd1btt1) and grew the resulting transformants overnight in 1M KCl
selective media. 1M KCl was selected because it has been shown to cause osmotic stress
(Slaninova, et al., 2000) and induce [PSI+] (Tyedmers, et al., 2008).

We then plated the

transformants and determined the [PSI+] strain induced for a minimum of 100 colonies per yeast
strain. The WT and nac strains showed similar [PSI+] strain distributions (Table 2.1), however
both the egd1egd2 and egd1btt1 strains had notable increases in very weak and weak
[PSI+], and decreases in medium and strong [PSI+] when compared to WT (Table 2.1). While not
perfectly correlative, this shift reflects the polyglutamine morphological differences we detected
in egd1btt1, indicating partial NAC deletion leads to potentially widespread changes in
protein folding.

2.4 Discussion
Our work shows that disruption of the NAC can be beneficial to cell survival in the face
of protein misfolding and aggregation stress. We have provided evidence that deletion of NAC
subunits leads to improved viability in cells overexpressing alpha-synuclein and htt exon1 103Q.
Furthermore, we have shown that htt exon1 103Q aggregation is delayed in egd1btt1 when
compared to htt exon1 103Q aggregation in WT, though expression of htt exon1 103Q is
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unchanged. Filter trap assays show that less htt exon1 103Q protein is aggregated after 6 hours
induction in egd1btt1 cells when compared to htt exon1 103Q aggregated protein in WT cells.
Interestingly, NAC disruption leads to changes in htt exon1 103Q aggregate morphology as well.
Lastly, we show that NAC disruption changes [PSI+] strain distributions when compared to WT.
This suggests that the NAC is an important factor in aggregate organization and that NAC
disruption may be capable of inducing widespread alterations in aggregate morphology.
Clearly, these counterintuitive results warrant further investigation. Beyond the main
results showing deletion of EGD1 and BTT1 leads to delayed and decreased aggregation of htt
exon1 103Q, we noticed that complete NAC deletion and deletion of EGD1 and EGD2 do not
result in robust rescue of cellular viability when htt exon1 103Q is expressed (Figure 2.1B). This
indicates that individual NAC subunits may have cellular roles that are important in protein
aggregation and maintaining cellular viability. Previous work showing variable rescue of
canavanine toxicity suggested this as well (Figure 1.3E) (Keefer and True, 2016).
Overall, this work shows that disruption of a chaperone complex has potential as a
therapeutic target in protein misfolding and aggregation conditions. Further investigation is
needed to understand how deletion of EGD1 and BTT1 leads to delayed and reduced htt exon1
103Q aggregation, htt exon1 103Q aggregate morphology changes, and de novo [PSI+] strain
induction. Potential avenues to address this will be proposed in Chapter 4.

2.5 Materials and methods
2.5.1 Yeast strains, plasmids, cultures, and transformations
All yeast strains are derivatives of 74-D694 (ade1-14 his3-200 leu2-3,112 trp1-289
ura3-52). Single and combinatorial genetic deletions of EGD1, EGD2, and BTT1 were made as
previously described (Keefer & True, 2016). Plasmids expressing huntingtin exon I fusions
43

controlled by the inducible GAL1 promoter (p416Gal1-FLAG-htt25QPro-CFP and p416Gal1FLAG-htt103QPro-CFP) were kindly gifted by S. Lindquist and were made as previously
described (Duennwald et al, 2006). Plasmids expressing alpha-synuclein constructs controlled by
the inducible GAL1 promoter (pRS426-Gal1-SNCAWT-GFP, pRS426-Gal1-SNCAA30P-GFP,
pRS426-Gal1-SNCAA53T-GFP) were kindly gifted by M. Jackrel. Egd1 and Egd2 overexpression
plasmids are under control of their endogenous promoters (p413-Egd1, p413-Egd2) and were
made using standard molecular biology techniques and confirmed by sequencing.

2.5.2 Antibodies
A monoclonal anti-FLAG antibody was obtained from Sigma-Aldrich. A monoclonal
anti-PGK1 antibody was obtained from ThermoFisher Scientific. A rabbit anti-mouse secondary
antibody was obtained from ThermoFisher Scientific.

2.5.3 Prion manipulation
WT and NAC deletion yeast strains transformed with p426-Sup35 plasmid were grown at
30°C for 16hrs with rotation in 1M KCl SD-ura media to induce de novo prion formation.
OD600 of each culture was determined and they were then plated on 150mm ¼ YPD solid media
plates at dilutions that would render 200-500 colonies. These plates were then incubated at 30°C
for 6 days and subsequently incubated at 4°C overnight for further color development. Each
colony was evaluated for color and scored [psi-] if red and [PSI+] if pink, white, or sectored. At
least 100 [PSI+] colonies were picked and pinned on ¼ YPD, SD-ade, and 5mM GdnHCl and
grown for 5 days at 30°C in order to evaluate [PSI+] strength and color change due to [PSI+]
induction. Each experiment was repeated at least 3 times.
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2.5.4 Fluorescent microscopy
Cells expressing p416Gal1-FLAG-htt25QPro-CFP, p416Gal1-FLAG-htt103QProCFP, or p414Gal1-EV were grown overnight in SD-ura. Cells were washed in S-ura, then grown
for indicated incubation time in S-ura, 2% galactose to induce expression of htt exon1 25Q or htt
exon1 103Q. Cells were imaged after 6 and 20 hours of induction using a x63 objective and cyan
filter on Zeiss LSM 880 airyscan two-photon confocal microscope. Images were blinded to
researcher and aggregation of htt exon1 103Q was assessed phenotypically. Collected data were
graphed and analyzed using GraphPad Prism version 8.1.1 for Windows, GraphPad Software, La
Jolla, California USA. Results represent a compilation of data collected during 3 separate
experiments.

2.5.5 Yeast phenotypic and growth assays
WT and all combinatorial deletions of NAC subunits harboring p416Gal1-FLAG-htt25QProCFP,

p416Gal1-FLAG-htt103QPro-CFP,

pRS426-Gal1-SNCAWT-GFP,

pRS426-Gal1-

SNCAA30P-GFP, pRS426-Gal1-SNCAA53T-GFP, or p416Gal1-EV were grown overnight in SDura. Cultures were normalized to 0.1 OD600 and spotted in 5 5-fold dilutions onto YPD, SD-ura,
S-ura, 2% galactose, 1% raffinose, S-ura, 2% galactose, 0.1% raffinose, and S-ura, 2% galactose.
A WT yeast strain harboring p413-Gal1-FLAG-103Q-GFP and pRS316-Egd2 or pRS316-Egd1
were grown overnight in SD-ura-his. Cultures were normalized to 0.1 OD600 and spotted in 5 5fold dilutions onto YPD, SD-ura-his, S-ura-his, 2% galactose, 1% raffinose, S-ura-his, 2%
galactose, 0.1% raffinose, and S-ura-his, 2% galactose. Induction plates were grown for 5 days at
30C and plates containing glucose were grown for 3 days at 30C. Experiments were repeated
at least 3 times.
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2.5.6 Protein analysis
Cells harboring p416Gal1-FLAG-htt25QPro-CFP, p416Gal1-FLAG-htt103QPro-CFP,
or p416Gal1-EV were grown overnight in SD-ura, washed 2x with S-ura, and induced for 6 or 20
hours in S-ura, 2% galactose. Cell lysates were prepared as previously described. Total protein
concentrations were determined by Bradford assays, normalized to ensure equal loading, and
mixed with SDS-PAGE sample buffer. Samples were boiled for 10 minutes at 100C before
loading onto 10% polyacrylamide gel and run at constant current of 100V. Blots were transferred
overnight, incubated with primary and secondary antibodies, and visualized with enhanced
chemiluminescence and film (GeneMate). Bands were analyzed and quantified with ImageJ and
normalized to PGK1. Experiments were repeated at least 3 times.

2.5.7 Filter trap assay
Followed modified protocol from Sin et al., 2018. Cells harboring p416Gal1-FLAGhtt25QPro-CFP, p416Gal1-FLAG-htt103QPro-CFP, or p414Gal1-EV were grown overnight
in SD-ura, washed 2x with S-ura, and induced for 6 hours in S-ura, 2% galactose. Cell lysates
were prepared as previously described. Lysates were normalized to 500ug total protein in Filter
Trap Assay Buffer and serially diluted three times at 1:2 dilutions. Resulting 2μ filter was
incubated

with

primary

and

secondary

antibodies,

and

visualized

with

enhanced

chemiluminescence and film (GeneMate). Bands were analyzed and quantified with ImageJ.
Ponceau staining was used as a loading control. Experiments were repeated at least 3 times.
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2.7 Figures

Figure 2.1 NAC modulation effects on amyloid-induced cytotoxicity (A) Yeast 74-D694 WT
and nac deletion strains expressing Gal1-inducible EV or A30P, WT, or A53T α-synuclein
constructs were serially diluted 5-fold and spotted onto ¼ YPD (not shown), SD-ura, and S-ura,
2% galactose (first 3 spots shown) to monitor α-synuclein toxicity and the ability of nac deletion
to rescue α-synuclein cytotoxicity (n=3). (B) Yeast 74-D694 WT and nac deletion strains
expressing Gal1-inducible EV, htt25Q, or htt103Q constructs were serially diluted 5-fold and
spotted onto ¼ YPD (not shown), SD-ura, and S-ura, 2% galactose (first 3 spots shown) to
monitor expanded polyglutamine toxicity and the ability of nac deletion to rescue expanded
polyglutamine cytotoxicity (n=3). (C) A yeast 74-D694 WT strain expressing EV, EGD2, or
EGD1 constructs in combination with Gal-inducible EV or htt103Q constructs were serially
diluted 5-fold on ¼ YPD (not shown), SD-ura-his, and S-ura-his, 2% galactose, 0.1% raffinose
47

(first three spots shown) to evaluate expanded polyglutamine toxicity and the ability of EGD1
and EGD2 overexpression to rescue expanded polyglutamine cytotoxicity (n=3).

Figure 2.2 NAC deletion effects on polyQ aggregation and aggregate distribution. (A) WT
and NAC deletion strains expressing Gal1-htt25Q-CFP or Gal1-htt103Q-CFP constructs were
grown in selective media in the presence of 2% galactose for 6 and 20 hours. Two-dimensional zstack images were taken with a Zeiss LSM 880 Airyscan Two-Photon Confocal Microscope with
a 63x oil immersion objective. The egd1btt1 strain showed a smaller population of cells with
aggregates than the WT or egd1egd2 strains at both time points. (B) Quantification of percent
cells expressing Gal1-htt25Q-CFP or Gal1-htt103Q-CFP constructs containing aggregates after 6
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hours induction by 2% galactose in selective media. Significance was determined by Fisher’s
exact test (****=<0.0001). (C) Quantification of percent cells expressing Gal1-htt25Q-CFP or
Gal1-htt103Q-CFP constructs containing aggregates after 20 hours induction by 2% galactose in
selective media. Significance was determined by Fisher’s exact test (****=p value<0.0001). (D)
Representative images of cells with 0, 1, 2, or 3 aggregates. Microscopy of WT and NAC
deletion strains expressing Gal1-htt25Q-CFP or Gal1-htt103Q-CFP constructs for 6 and 20 hours
were evaluated based on this scale. (E) WT and NAC deletion strain cells expressing Gal1htt103Q-CFP constructs for 6 or 20 hours and containing aggregates were evaluated as having 1,
2, or 3 or more aggregates. The resulting population distributions are represented as percentages
in pie graphs.

Figure 2.3 WT and NAC deletion strains express similar levels of polyQ protein and polyQ
aggregation is reduced in egd1btt1. (A) WT and NAC deletion strains expressing Gal1FLAG-htt25Q-CFP or Gal1-FLAG-htt103Q-CFP constructs were grown in selective media in the
presence of 2% galactose for 6 hours prior to SDS-PAGE and Western blotting for FLAG and
PGK1. Western blots are representative images of three independent experiments. (B) WT and
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NAC deletion strains expressing Gal1-FLAG-htt25Q-CFP (not shown) or Gal1-FLAG-htt103QCFP constructs were grown in selective media in the presence of 2% galactose for 6 hours prior
to Filter Trap Assay and Western blotting for FLAG. All strains in figure are expressing Gal1FLAG-htt103Q-CFP. Western blot is a representative image of three independent experiments.
(C) Quantification and normalization to WT of 3 independent Filter Trap Assay Western blots
represented in 3(B), data are represented as mean ± SEM, significance was determined by paired
t-test, *=p value<0.05, and ns=p value>0.05.

[PSI+] strain
Wild Type
nac
egd1egd2
egd1btt1
Very Weak
8.05.0%
10.74.3%
19.16.1%
17.13.8%
Weak
26.96.2%
28.85.2%
38.03.9%
35.33.0%
Medium
54.18.4%
52.67.9%
40.73.2%
41.63.7%
Strong
11.02.6%
8.01.1%
2.32.3%
6.12.4%
+
Table 2.1 [PSI ] distribution is altered in NAC deletion strains. WT and NAC deletion strains
expressing a pEMBL-SUP35 construct were grown overnight in selective media containing 1M
KCl, plated, and evaluated for [PSI+] prion strength by a previously described colorimetric
assay. Over 100 colonies were evaluated from three independent experiments and ±values=SEM.

Log #
Plasmid
Auxotrophic Marker
Control
SL7711 p416-Gal1-FLAG-25Q-CFP
URA3
X
SL7712 p416-Gal1-FLAG-103Q-CFP
URA3
SL7874 p413-Gal1-FLAG-103Q-GFP
HIS3
SL9250 P413-Gal1
HIS3
X
SL9256 p416-Gal1
URA3
X
5320
pRS316-Egd2
URA3
5328
pRS316-Egd1
URA3
6244
p426-Sup35
URA3
6890
pRS426-Gal1-SNCAWT-GFP
URA3
A30P
6891
pRS426-Gal1-SNCA
-GFP
URA3
6892
pRS426-Gal1-SNCAA53T-GFP
URA3
Table 2.2 Plasmids used in this study. The left-most column indicates the True Lab log number
of each plasmid, the second from the left column contains the plasmid names, the third from the
left column indicates the auxotrophic marker of each plasmid, and the right most column
identifies the control plasmids.
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Log #
Strain Information
3233
74D-694, [RNQ+], [psi-], Mat A
3234
74D-694, [RNQ+], [psi-], egd1, Mat A
3235
74D-694, [RNQ+], [psi-], egd2btt1, Mat A
3236
74D-694, [RNQ+], [psi-], nac, Mat A
3237
74D-694, [RNQ+], [psi-], egd2, Mat A
3238
74D-694, [RNQ+], [psi-], egd1egd2, Mat A
3239
74D-694, [RNQ+], [psi-], btt1, Mat A, HIS+
3240
74D-694, [RNQ+], [psi-], egd1btt1, Mat A HIS+
Table 2.3 Strains used in this study. The left most column indicates the True Lab log number
of each strain and the right column contains relevant strain information.

Supporting Figure S1: Ponceau staining shows similar protein concentrations loaded in
filter trap assay. WT and NAC deletion strains expressing Gal1-FLAG-htt25Q-CFP (not shown)
or Gal1-FLAG-htt103Q-CFP constructs were grown in selective media in the presence of 2%
galactose for 6 hours prior to Filter Trap Assay and Western blotting for FLAG. After developing
2μ filter was soaked in Ponceau staining to show total protein load. All strains are expressing
Gal1-FLAG-htt103Q-CFP.
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Chapter 3: Evaluating Second-Site
Suppressors of LGMDD1 Mutations

This work is based on a second-site suppressor screen described in section 3.3.1. All experiments
in subsequent sections are original to this work and were solely conducted by Leeran Blythe
Dublin-Ryan.
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3.1 Abstract
Chaperonopathies are conditions caused by mutations in molecular chaperones. LimbGirdle Muscular Dystrophy Type 1D (LGMDD1) is a chaperonopathy associated with many
mutations in the Hsp40 DNAJB6, spanning the J and G/F domains of the protein. Functional
studies of DNAJB6 in multicellular organisms are challenging, as a known substrate of DNAJB6
has not yet been discovered. Sis1 is a yeast homolog of DNAJB6 with known client substrates.
The existence of a homolog in Saccharomyces cerevisiae provides a compelling system for
studying the effects of LGMDD1-associated mutations. Previous work has shown that mutations
in the G/F-domain of DNAJB6 cause disruption of chaperone activity and client processing in
Sis1 and a DNAJB6/Sis1 chimeric protein, SDSS. We show here that multiple second-site
suppressors in the J-domain of Sis1 are capable of rescuing the activity defects caused by two
different G/F-domain mutations. This work shows the viability of second-site suppressors in
rescuing Hsp40 activity and shows great potential as a therapeutic strategy in the treatment of
LGMDD1.

3.2 Introduction
Because chaperones are vitally important for innumerous protein folding events,
mutations in chaperones can lead to modulation of activity and disease. Diseases induced by
chaperone mutations are known as chaperonopathies (Macario and Conway de Macario, 2007).
For example, LGMDD1 is associated with a myriad of mutations in the G/F and J domains of
DNAJB6 (Harms et al., 2012; Sarparanta et al., 2012; Sato et al., 2013; Couthouis et al., 2014;
Suarez-Cedeno et al., 2014; Yabe et al., 2014; Nam et al., 2015; Palmio et al., 2015; Ruggieri et
al., 2015; Bohlega et al., 2018; Kim et al., 2018; Zima et al., 2019; Palmio et al., 2020). DNAJB6
53

is an Hsp40 that participates with Hsp70s to induce proper protein folding (Cyr et al., 1992;
Freeman et al., 1995).
While it is known that many mutations in DNAJB6 are causative of LGMDD1, little is
known about the cellular mechanism by which mutations in the protein induce disease
phenotypes. Likewise, a known substrate of DNAJB6 remains elusive, making studying the
mechanisms of the protein more difficult. Luckily, there is a yeast homolog of DNAJB6, the
essential Hsp40 Sis1, with multiple known substrates, including Rnq1 and Sup35, which form
the prions [RNQ+] and [PSI+], respectively. The introduction of LGMDD1-associated mutations
in a Sis1 and DNAJB6 chimeric protein, SDSS, resulted in a reduced ability to propagate [RNQ+]
and [PSI+] prions (Stein, et al., 2014). While DNAJB6 could not be used in these experiments
because it cannot compensate for other Sis1 activities involved in cellular viability, the presence
of another human J-protein, DNAJB1, is able to confer viability in sis1 cells and was used for
further experimentation (Stein et al., 2014). One experiment revealed that DNAJB1-F90I
(homologous to the LGMDD1-associated mutation DNAJB6-F89I) showed robust loss of
viability (Stein et al., 2014). This result was of particular interest because it is useful for a
second-site suppressor screen.
Suppression genetics has been used as a tool for understanding interactions between
different proteins and different domains of the same proteins for decades (Hodgkin, 2005). A
second-site suppressor is a secondary mutation that reverts a phenotype caused by a primary
mutation back to the WT phenotype. There are two types of second-site suppressor mechanisms
of action. Second-site suppressors can act in an intragenic manner, meaning the second-site
suppressor is located in the same gene as the primary mutation, or in an intergenic manner,
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meaning the second-site suppressor is located in a different gene than the primary mutation.
Most Type I and Type II Hsp40s form functional homodimers, including Sis1, DNAJB1, and
DNAJB6, so an intragenic second-site suppressor could act within one Hsp40 molecule or cause
reversion to the WT phenotype through extra-molecular interactions between two Hsp40
molecules (Kampinga and Craig, 2010; Sha et al., 2000; Hu et al., 2008; Söderberg et al., 2018).
A requirement for second-site suppressor screening is a fairly robust primary phenotype,
which we found in the stark DNAJB1-F90I-induced loss of viability. The yeast model organism
in which this phenotype was found provided a tractable genetic system for a second-site
suppressor screen. Moreover, the previous work that established clear [RNQ+] and [PSI+]
propagation defects resulting from LGMDD1 mutations provided an experimental scaffolding to
evaluate the effects of resulting second-site suppressors. Here we report the discovery of multiple
second-site suppressors of DNAJB1-F90I. We also show that two of these second-site
suppressors are particularly effective in rescuing activity defects caused by two LGMDD1associated mutants. This work shows the potential of second-site suppressors as viable therapies
and sets the stage for further studies to understand the mechanism by which these second-site
suppressors act.

3.3 Results
3.3.1 Identification of second-site suppressors of DNAJB1-F90I
As previously described in Chapter 1, there are many mutations in J and G/F domains of
DNAJB6 that are associated with LGMDD1 (Harms et al., 2012; Sarparanta et al., 2012; Sato et
al., 2013; Couthouis et al., 2014; Suarez-Cedeno et al., 2014; Yabe et al., 2014; Nam et al., 2015;
Palmio et al., 2015; Ruggieri et al., 2015; Bohlega et al, 2018; Kim et al., 2018; Zima et al.,
2019; Palmio et al., 2020). These LGMDD1-associated mutations in the DNAJB6 J and G/F
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domains have been extensively studied in yeast and multicellular organisms, however our
understanding of their effect at the cellular level in the context of disease is limited. Kevin Stein
(a former graduate student in the True lab) found that some G/F domain mutants caused
disruption in propagation of particular [RNQ+] and [PSI+] variants (Stein et al., 2014). He also
found that introducing an F90I mutation in DNAJB1 (homologous to DNAJB6-F89I) caused a
viability defect in sis1 cells (Figure 3.1A). This strong phenotype was well-suited for a secondsite suppressor screen, which is beneficial for uncovering new insights into protein domain
interactions and effects of primary mutations.
Sis1 is required for viability and DNAJB1 can compensate for Sis1 loss. Therefore,
Kevin performed error-prone PCR on a DNAJB1-F90I construct, creating a library of DNAJB1F90I constructs that had additional mutations introduced. He grew a 74-D694 [RNQ+], [psi-],
sis1 strain that was transformed with a URA3-marked, WT SIS1 plasmid (pRS316-SIS1),
transformed the strain with the library of potential DNAJB1-F90I mutants, and selected for loss
of the WT SIS1 plasmid by growing the transformants on 5-fluoroorotic acid (5-FOA). The
viable colonies resulting from this process should only contain the DNAJB1-F90I library
constructs. Resulting colonies were then tested to determine if their viability was due to rescue
by a second-site suppressor. From this screen Kevin identified six second-site suppressors
(Figure 3.1A), two of which (DNAJB1-R22W and R26G) were used in the subsequent
experiments described herein.

3.3.2 Two second-site suppressors are located near a conserved Hsp40 motif
The DNAJB1-R22W and DNAJB1-R26G (homologous to DNAJB6-K21W and
DNAJB6-K25G and Sis1-K24W and Sis1-K28G, Figure 3.1B) second-site suppressors are of
particular interest because they are located near the HPD motif, which is a conserved motif
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important for J-protein interaction with HSP70s (Tsai and Douglas, 1996), and multiple potential
(unconfirmed) LGMDD1-associated mutations. We set out to evaluate the ability of these
second-site suppressors to rescue chaperone activity by assessing the prion propagation defects
caused by LGMDD1-associated mutations in the DNAJB6 G/F domain. Thus, we decided to use
the SDSS chimeric protein that compensates for sis1 loss and harbors the DNAJB6 G/F domain.
This protein is constructed of the Sis1 J-domain, the DNAJB6 G/F domain, the Sis1 G/M
domain, and the Sis1 CTD (Figure 3.1B) and has been successfully used to study DNAJB6 G/F
domain mutations in the past (Stein et al, 2014). The second-site suppressors were introduced in
SDSS-F89I, which is homologous to DNAJB1-F90I (Figure 3.1B), and in SDSS-WT. This
resulted in four plasmid constructs, each expressing one of the following proteins: SDSS-K24W,
SDSS-K28G, SDSS-K24W-F89I, and SDSS-K28G-F89I.

3.3.3 Second-site mutations K24W and K28G have varied effects on [PSI+]
propagation defect resulting from F89I mutation
As described in Chapters one and two, yeast prions are non-cytotoxic and many are
clients of Sis1. Specifically, [RNQ+] and [PSI+] require Sis1 for propagation (Sondheimer et al.,
2001; Higurashi et al., 2008). SDSS-WT is able to compensate for sis1 loss and SDSS-F89I was
previously shown to disrupt weak [PSI+] and Sc37 propagation (Figure 1.4D) (Stein et al., 2014).
Therefore, we transformed weak [PSI+] and Sc37 sis1 strains harboring pRS316-SIS1 with
plasmid constructs expressing SDSS-WT, SDSS-F89I, SDSS-K24W, SDSS-K28W, SDSSK24W-F89I, and SDSS-K28W-F89I, grew the resulting transformants on 5-FOA to select for the
loss of pRS316-SIS1, and performed a viability assay with the resulting colonies (Figure 3.2).
After growth on 5-FOA these colonies only express the SDSS constructs, which are on TRP1marked plasmids. [PSI+] propagation was disrupted as a result of SDSS-F89I expression (Figure
3.2), consistent with previous results (Stein et al., 2014). Interestingly, we saw that Sc37
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propagation was partially maintained in colonies containing SDSS-K24W-F89I (Figure 3.2).
Furthermore, we observed uniform maintenance of [PSI+] propagation in colonies containing
SDSS-K28G-F89I (Figure 3.2).
Intrigued by the heterogeneity of results in the SDSS-K24W-F89I Sc37 colonies, we
decided to take a closer look at [PSI+] propagation in these strains. To do this we grew the Sc37
strain containing TRP1-marked plasmids expressing SDSS-WT, SDSS-F89I, SDSS-K24W,
SDSS-K28W, SDSS-K24W-F89I, and SDSS-K28W-F89I and the weak [PSI+] strain containing
TRP1-marked plasmids expressing SDSS-WT, SDSS-F89I, SDSS-K28W, and SDSS-K28WF89I in SD-trp media overnight and plated them at concentrations that would result in 200-500
colonies per plate. We then evaluated the resulting colonies by color, recording the number of
[PSI+] and [psi-] colonies. As expected, the SDSS-WT containing colonies maintained [PSI+] at
nearly 100% in both the Sc37 and weak [PSI+] strains (Figure 3.3). Expression of SDSS-F89I led
to almost total loss of [PSI+] propagation in the Sc37 strain (Figure 3.3A) and loss of weak
[PSI+] propagation in approximately 75% of colonies (Figure 3.3B). The introduction of K28G
in combination with F89I led to robust rescue of the SDSS-F89I [PSI+] propagation defect in
both the weak [PSI+] and Sc37 strains (Figure 3.3). While the addition of K24W to SDSS-F89I
led to a modest increase in weak [PSI+] propagation, this change was not significant when
compared to the strain expressing SDSS-F89I alone (Figure 3.3A).

3.3.4 K24W and K28G rescue [PSI+] propagation defect caused by another
LGMDD1-associated mutation
Encouraged by these results, we wanted to investigate whether the K24W and K28G
second-site suppressors were effective in combination with other LGMDD1 mutations. Because
these second-site suppressors are not currently predicted to interact with the G/F domain and are
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within close proximity to the HPD-motif, we hypothesize they may alter aspects of J-protein
interaction with Hsp70s. Because of this we expected that they may be effective in rescuing
defects resulting from other LGMDD1-associated mutations. Thus, we introduced the secondsite suppressors in Sis1 in combination with F106L and F115I, which are homologous to
LGMDD1-associated mutations DNAJB6-F93L and DNAJB6-F100I (Figure 3.1B).
We transformed the Sc37 and Weak [PSI+] sis1 strains expressing Sis1-WT on a
URA3-marked plasmid with TRP1-marked plasmids expressing Sis1-WT, Sis1-F106L, Sis1F115I, Sis1-K24W, Sis1-K28G, Sis1-K24W-F106L, Sis1-K24W-F115I, Sis1-K28G-F106L, and
Sis1-K28G-F115I. We then grew these transformants on 5-FOA to select for loss of the URA3marked SIS1-WT plasmid. Cells that grew on 5-FOA containing medium were grown in SD-trp
liquid medium overnight, diluted to an OD of 0.1, serially diluted 5-fold, and spotted on SD-trp,
¼ YPD and SD-ura (to confirm loss of the URA3-marked SIS1 plasmid). Expression of the Sis1F106L mutation did not cause loss of the [PSI+] prion (data not shown). This result meant we
could not evaluate the addition of the second site suppressors, as there was no apparent
phenotypic difference between Sis1-WT and Sis1-F106L expressing colonies. However,
expression of Sis1-F115I resulted in partial loss of [PSI+] propagation in both the Sc37 and weak
[PSI+] strains. In addition, the introduction of K28G in Sis1-F115I led to rescue of the partial
[PSI+] propagation defect in both the Sc37 and weak [PSI+] strains (Figure 3.4). Introduction of
K24W in Sis1-F115I resulted in a mixed population of red and pink colonies in both the Sc37
and [PSI+] strains, indicating some [PSI+] propagation loss (Figure 3.4).
Once again, we wanted to further evaluate [PSI+] propagation in these cells, so we grew
Sc37 and Weak [PSI+] sis1 strains transformed with TRP1-marked plasmids expressing Sis159

WT, Sis1-F115I, Sis1-K24W, Sis1-K28G, Sis1-K24W-F115I, and Sis1-K28G-F115I in SD-trp
medium overnight. We plated the cultures on ¼ YPD 150mm plates at concentrations that would
render 200-500 colonies per plate, and evaluated the resulting colonies by color. We
photographed representative plates to show the resulting phenotypes (Figure 3.5A), and recorded
the number of [PSI+] and [psi-] colonies in the weak [PSI+] strains transformed with TRP1marked plasmids expressing Sis1-WT, Sis1-F115I, Sis1-K24W, Sis1-K28G, Sis1-K24W-F115I,
and Sis1-K28G-F115I (Figure 3.5B). In both the Sc37 and weak [PSI+] strains we noted the
marked increase of red ([psi-]) colonies upon the introduction of the Sis1-F115I mutation, which
was reduced when introduced in combination with K28G (Figure 3.5A). Furthermore, while the
expression of Sis1-F115I led to a 20% reduction in colonies propagating [PSI+] as compared to
Sis1-WT colonies, introduction of either K24W or K28G in combination with F115I led to the
rescue of this mutation-induced [PSI+] propagation defect (Figure 3.5B). These results revealed
that the two second-site suppressors are effective in rescuing defects induced by multiple
LGMDD1-associated mutations and warrant further investigation into the mechanism of action
of this rescuing effect.

3.4 Discussion
While these data are encouraging, much work is left to be done to understand the effects
of these second-site suppressors on LGMDD1-associated mutations. Through these experiments
we have learned that the K28G second-site suppressor may be more effective in rescuing defects
caused by LGMDD1-associated mutations. We have also seen that these second-site suppressors
may be capable of rescuing defects resulting from a wide range of LGMDD1-associated
mutations. This could be because these second-site suppressors affect the tertiary or quaternary
structures of the SDSS or Sis1 mutants and, possibly, DNAJB6 mutants. Conversely, the second60

site suppressors could modulate interactions with Hsp70, perhaps creating conditions that are
favorable for some recovery of chaperone activity by the protein.
The next steps of this project are to use an arsenal of in vitro assays to evaluate the
second-site suppressors effect on various aspects of the Hsp40/70 cycle, including ATPase
activity, substrate-binding activity, HSP40/70 binding, and Hsp40 dimerization. We will also
examine the ability of the second-site suppressors to influence [RNQ+] prion propagation in order
to determine if the results we have seen are substrate specific. We hypothesize that the addition
of second-site suppressors will result in key differences in at least one stage of the HSp40/70
cycle.

3.5 Materials and methods
3.5.1 Yeast cultures, transformations, and plasmid shuffling
Spottings and [PSI+] induction assays were performing using derivatives of 74-D694
(ade1-14 his3-Δ200 leu2-3,112 trp1-289 ura3-52), are [psi-], [PSI+], [rnq-], or [RNQ+], and were
kindly gifted by Sue Liebman and Jonathan Weissman. Yeast strains were cultured using
standard techniques. YPD (1% yeast extract, 2% peptone, 2% dextrose) or synthetic defined
(SD) media (0.67% yeast nitrogen base without amino acids, 2% dextrose) lacking specific
amino acids. In order to study the function of second-site suppressors in SDSS and Sis1 we used
sis1 cells that were previously transformed with a pRS316-SIS1 plasmid. We then transformed
these cells with a pRS314 plasmid carrying sdss or sis1 mutants as described in the results
section. We plated these transformants first on SD-trp media to select for the mutant plasmids,
then grew the colonies on plates containing 5-fluoroorotic acid (5-FOA) to select for colonies
that had lost the pRS316-SIS1 plasmid. All plasmid transformations were performed using the
standard PEG/LiOAc method. The SDSS chimera plasmid was made and used in the True lab by
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Kevin Stein (Stein et al., 2014). The pRS316-SIS1 plasmid was kindly gifted by E. Craig. Any
other plasmids used are described in the results section and were constructed using standard
molecular techniques.

3.5.2 Plasmid construction
SDSS mutants were created using site directed mutagenesis as described previously
(Stein et al., 2014; Pullen, 2020). Using pRS314-SIS1, F106L and F115I mutants were generated
using the Quick Change Mutagenesis Kit (Agilent Technologies #200517). Second-site
suppressors were created using the Takara in-fusion cloning site-directed mutagenesis system.
Mutagenesis was confirmed by sequencing the entire coding region of Sis1.

3.5.3 Yeast spotting assay
Cultures were grown overnight in selective media. OD600 of each culture was
determined. Each culture was normalized to an optical density of 0.1 and spotted in 5 5-fold
serial dilutions on ¼ YPD, SD-ura, 5-FOA, and SD-trp using an ethanol-sterilized 48-pin
replicator. Spottings were grown at 30°C for 5 days, incubated overnight at 4°C for further color
development before being photographed. Each experiment was repeated 3 times.

3.5.4 [PSI+] propagation frequency
74-D694 yeast containing the indicated strains of [PSI+] and expressing the indicated sis1
or sdss mutants were grown at 30°C for 16hrs with rotation. OD600 of each culture was
determined and they were then plated on 150mm ¼ YPD solid media plates at dilutions that
would render 200-500 colonies. These plates were then incubated at 30°C for 6 days and
subsequently incubated at 4°C overnight for further color development. Each colony was
evaluated for color and scored [psi-] if red and [PSI+] if pink, white, or sectored. Each experiment
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was repeated at least 3 times. Resulting data were analyzed and graphed using GraphPad Prism
version 8.1.1 for Windows, GraphPad Software, La Jolla, California, USA.
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3.7 Figures

Figure 3.1 Identification of intragenic second-site suppressors and Hsp40s homology.
(A) Screen performed by Kevin Stein. Spottings are from the same plate and are labeled by
second-site suppressor. (B) Top illustration denotes the different domains of DNAJB1 (orange),
Sis1 (blue), DNAJB6b (green), and SDSS (blue J, G/M, and CTD; green G/F). Middle insets
indicate two second-site suppressors in each Hsp40 and relevant LGMDD1 mutations in each
Hsp40. Bottom is the legend for the colors used to highlight specific second-site suppressors and
LGMDD1 mutations in the middle insets.
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Figure 3.2 Second-site suppressors K24W and K28G do not affect viability and rescue
prion propagation disrupted by F89I mutation. Yeast sis1 cells harboring the indicated
SDSS expressing constructs in Sc37 and weak [PSI+] were serially diluted 5-fold and spotted on
media selecting for the constructs (n=3).

Figure 3.3 Second-site suppressor mutation K28G rescues [PSI+] propagation defect
resulting from F89I mutation. Yeast sis1 cells harboring the indicated SDSS expressing
constructs in (A) Sc37 and (B) weak [PSI+] were grown overnight in selective media and plated
at concentrations to render 200-500 colonies per plate. Plates were incubated and subsequent
colonies were evaluated by color to determine if they were [PSI+] or [psi-] (n=3). * indicates p
value < 0.05, ** indicates p value < 0.01.
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Figure 3.4 Sis1-F115I does not affect viability and induces prion loss, which second-site
suppressors K24W and K28G partially rescue. Yeast sis1 cells harboring the indicated Sis1
expressing constructs in Sc37 and weak [PSI+] were serially diluted 5-fold and spotted on media
selecting for the constructs (n=3).
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Figure 3.5 Sis1-F115I induces prion loss, which is significantly rescued by introduction of
second-site suppressors K24W and K28G. Yeast sis1 cells harboring the indicated Sis1
expressing constructs in Sc37 and weak [PSI+] were grown overnight in selective media and
plated at concentrations to render 200-500 colonies per plate. Plates were incubated and
subsequent colonies were evaluated by color to determine if they were [PSI+] or [psi-] (n=3).
Phenotypes can be seen in (A) and the resulting percent [PSI+] in the weak [PSI+] transformants
can be seen in (B). (n=3), ** indicates p value < 0.01.

Log #
Plasmid
Auxotrophic Marker
Control
5691
pRS316-SIS1
URA3
6404
pRS314-SIS1
TRP1
X
6405
pRS314-sis1-F106L
TRP1
X
6552
pRS314-sis1-F115I
TRP1
X
6581
pRS314-SDSS
TRP1
X
6600
pRS314-sdss-F89I
TRP1
X
6863
pRS314-sdss-K24W
TRP1
X
6864
pRS314-sdss-K28G
TRP1
X
6865
pRS314-sdss-G68E
TRP1
X
6868
pRS314-sdss-K24W-F89I
TRP1
6869
pRS314-sdss-K28G-F89I
TRP1
6870
pRS314-sdss-G68E-F89I
TRP1
6893
pRS314-sis1-K24W
TRP1
X
6894
pRS314-sis1-K28G
TRP1
X
6895
pRS314-sis1-K24W-F106L
TRP1
6896
pRS314-sis1-K28G-F106L
TRP1
6897
pRS314-sis1-K24W-F115I
TRP1
6898
pRS314-sis1-K28G-F115I
TRP1
Table 3.1 Plasmids used in this study. The left-most column indicates the True Lab log number
of each plasmid, the second from the left column contains the plasmid names, the third from the
left column indicates the auxotrophic marker of each plasmid, and the right most column
identifies the control plasmids.
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Log #
Strain Information
Plasmid
+
2384
5691
74D-694, Weak [PSI ], sis1, Mat alpha, ADE+, URA+
+
2470
5691
74D-694, Sc37 [PSI ], sis1, Mat A, ADE+, URA+
2879
5691
74D-694, [rnq ], [psi ], sis1, Mat alpha, URA+
+
3562
6581
74D-694, Weak [PSI ], sis1, Mat alpha, ADE+, URA+
+
3563
6600
74D-694, Weak [PSI ], sis1, Mat alpha, ADE+, URA+
+
3564
6869
74D-694, Weak [PSI ], sis1, Mat alpha, ADE+, URA+
+
3565
6864
74D-694, Weak [PSI ], sis1, Mat alpha, ADE+, URA+
+
3566
6581
74D-694, Sc37 [PSI ], sis1, Mat A, ADE+, URA+
+
3567
6600
74D-694, Sc37 [PSI ], sis1, Mat A, ADE+, URA+
+
3568
6863
74D-694, Sc37 [PSI ], sis1, Mat A, ADE+, URA+
+
3569
6864
74D-694, Sc37 [PSI ], sis1, Mat A, ADE+, URA+
+
3570
6868
74D-694, Sc37 [PSI ], sis1, Mat A, ADE+, URA+
+
3572
6869
74D-694, Sc37 [PSI ], sis1, Mat A, ADE+, URA+
3573
6581
74D-694, [rnq ], [psi ], sis1, Mat alpha, URA+
Table 3.2 Strains used in this study. The left most column indicates the True Lab log number
of each strain, the middle column contains relevant strain information, and the right most column
identifies the plasmid harbored in each strain.
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Chapter 4: Conclusions and Future
Directions
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4.1 Summary
Chapter 1 outlines the current understanding of molecular chaperones and their roles in
protein folding and misfolding, chaperonopathies, and maintaining cellular homeostasis.
Furthermore, the chapter reviews prion proteins, prions in yeast, human aggregate-prone
proteins, and using yeast as a model system for investigating protein misfolding and aggregation.
Chapter 2 presents data suggesting that disruption of a particular molecular chaperone complex,
the NAC, is a possible therapeutic target for polyglutamine misfolding. This work shows that
deletion of two NAC components, Egd1 and Btt1, leads to delayed and reduced polyglutamine
aggregation and improved viability in the face of aggregation-induced cytotoxicity. Moreover,
this combinatorial deletion changes the distribution of polyglutamine aggregates within the cell.
Lastly, this chapter shows that NAC disruption changes the distribution of [PSI+] strains as well.
This work builds on a growing project showing chaperone disruption can be effective in
combating toxic aggregation. Chapter 3 uses an innovative genetic system to investigate possible
mechanisms for rescuing LGMDD1-associated mutation effects. This chapter shows that two
second-site suppressors near the conserved HPD-motif are able to rescue [PSI+] propagation
defects caused by multiple LGMDD1-associated mutations. This work shows great promise for
both in vitro studies to better understand the mechanism by which they rescue and translation
into more complex disease models, such as tissue culture or animal models.
While the goals and findings of these chapters are different and seemingly disconnected,
they both identify potential therapeutic avenues for treating protein misfolding diseases. We
hope that future work will identify the mechanisms by which these genetic modulations affect
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protein aggregation and chaperone activity and that they will lead to novel and effective
therapeutic strategies.

4.2 Future Directions
Studying human diseases at the organism or tissue level can be extremely challenging;
yeast present a system in which genetic manipulation is more accessible and mechanistic studies
are less complex and laborious to implement. Thus, it is not surprising that many mechanistic
insights have been made using yeast models. The work described in chapters 2 and 3 sets the
stage for examining the mechanisms of action that lead to reduced polyglutamine aggregation
and cytotoxicity and rescue of defects resulting from LGMDD1-associated mutation.

4.2.1 Elucidating the mechanism by which NAC disruption affects
polyglutamine aggregation and toxicity
Determine the importance of EGD2 expression in the egd1btt1 strain effects on polyglutamine
aggregation and toxicity
Chapter 2 highlights the novel discovery that NAC disruption affects polyglutamine
aggregation and toxicity, however the mechanism by which this occurs remains unknown. In
yeast there are three NAC subunits, Egd1, Egd2, and Btt1. Egd1 and Btt1 are known as the β and
β’ subunits and are responsible for reversibly binding the complex to the ribosome (Reimann et
al., 1999). Because the egd1btt1 strain lacks these subunits we have hypothesized that Egd2 is
not interacting with nascent polypeptides at the ribosome, but this has not been confirmed.
Furthermore, even if our hypothesis is correct and Egd2 is not localizing to the ribosome and
interacting with nascent polypeptides, Egd2 has other roles in the cell (Shi et al., 1995; Franke et
al., 2001; Meury et al., 2010) and it is important to understand if these roles are affecting
polyglutamine aggregation and toxicity. It is known that Egd2 has a UBA domain, which
stabilizes the protein (Panasenko et al., 2006). Deletion of the Egd2 UBA domain has been
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shown to alter Egd2 chaperone activity and stability (Panasenko et al., 2006; Panasenko et al.,
2009; Ott et al., 2015). In order to assess whether Egd2 activity and stability are required for the
effects of the egd1btt1 strain on polyglutamine aggregation, an egd2-UBA construct would
be expressed in the nac strain, along with expanded-polyQ. If expression of this construct in the
nac strain resulted in recapitulation of the egd1btt1 phenotypes then it would be determined
that the presence of Egd2, but not its chaperone activity or stability, is required for the
phenotypes observed in the egd1btt1 strain expressing expanded polyglutamine. Conversely,
if the nac strain expressing the egd2-UBA and expanded polyglutamine constructs does not
phenocopy the egd1btt1 strain it would be determined that stable Egd2 is required for the
phenotypes we have observed in the egd1btt1 strain expressing expanded polyglutamine.
Because the reduction in expanded polyglutamine-induced cytotoxicity seen in the egd1btt1
strain was not observed in the egd1egd2 and nac strains we hypothesize that the presence of
stable Egd2 is required for the egd1btt1 phenotypes.
Investigate egd1btt1 effects on protein misfolding responses
It is known that modulation of molecular chaperones can change the effectiveness
(Chernoff et al., 1999) and cellular distribution of other molecular chaperones (Keefer and True,
2016). While previous work has shown that NAC deletion does not globally change the
expression levels of many other molecular chaperones (Ssb, Ssa, Sis1, Hsp104) (Keefer and
True, 2016), it remains unknown if disruption of the NAC leads to modulation of other
components of the molecular chaperone and protein folding network. It is known that heat stress
in HeLa cells leads to downregulation of Egd2 and that depletion of Egd2 in HeLa cells activates
multiple ER stress proteins, including BiP, CHOP, and phosphorylated PERK (Hotokezaka et al.,
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2009). Because expanded polyglutamine has been shown to activate the Unfolded Protein
Response pathway (Duennwald et al., 2006) we hypothesize that the mechanism by which
egd1btt1 reduces expanded polyglutamine cytotoxicity and aggregation could involve
alterations to the activation of the UPR. To test this hypothesis, western blots of the WT and nac
deletion strains before expression of expanded polyglutamine, 6 hours after induction, and 20
hours after induction would be performed and the resulting membranes would be probed for
Kar2 (yeast homolog of Bip) and Ire1. There are many possible outcomes from this experiment.
The deletion of egd1 and btt1 could create a cellular environment where Egd2 is no longer
localized to ribosomes and instead participates in suppressing the UPR. This would lead to low
signal of Kar2 and Ire1 at every time point. The deletion of egd1 and btt1 could destabilize Egd2,
leading to induction of the UPR, which would result in increased Kar2 and Ire1 at every time
point. There are also possibilities of one of the above scenarios occurring, but the expression of
expanded polyglutamine modulates Egd2 stability in a way that leads to downstream changes in
UPR activation. In any case these experiments would likely provide new insights into NAC
disruption’s effect on the cellular response to expanded polyglutamine expression.
Determine ability of Egd1 and Btt1 expression to rescue expanded polyglutamine aggregation
and toxicity
It has been determined that loss of egd1 and btt1 leads to delayed aggregation and
reduced cytotoxicity of expanded polyglutamine, however it remains unknown if loss of certain
cellular roles of these subunits could be sufficient for these phenotypes. This could be important,
as total loss of the NAC is lethal in multicellular organisms (Deng and Behringer, 1995; Bloss et
al., 2003) and interruption of certain cellular roles could allow for effective treatment of protein
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misfolding diseases without harming the cell. Both Egd1 and Btt1 have ribosome binding
domains that can be disrupted while maintaining the domains required for dimerization and
interacting with nascent polypeptides (Ott et al., 2015). Constructs of either ribosome-binding
impaired Egd1 or Btt1 could be introduced in the egd1btt1 strain, along with expression of
expanded polyglutamine. The strains could then be examined via fluorescent microscopy,
western blotting, and spotting assays to determine the ability of expanded polyglutamine to
aggregate and cause toxicity. If the cells expressing expanded polyglutamine and the Egd1 or
Btt1 mutants phenocopy wild type expressing expanded polyglutamine then it could be
concluded that the presence of Egd1 or Btt1 in the cell is sufficient to rescue expanded
polyglutamine aggregation and toxicity. If the cells expressing expanded polyglutamine and the
Egd1 or Btt1 ribosome-binding impaired mutants continue to reduce cytotoxicity and expanded
polyglutamine aggregation, then it can be determined that Egd1 or Btt1 ribosome binding is
required for polyglutamine aggregation and cytoxicity. Either result would allow for better
understanding the importance of ribosome binding in the activity of the NAC and the relevance
of this activity in protein aggregation. It is possible that abolishing NAC association with the
ribosome could allow localization of the complex to expanded polyglutamine, which could
invoke stronger reduction of aggregation and toxicity reduction.
Elucidate Egd2 localization in egd1btt1 cells expressing expanded polyglutamine
Finally, it is important to understand the localization of Egd2 in egd1btt1 cells
expressing expanded polyglutamine. A fluorescent tag should be added to Egd2 and confocal
microscopy should be performed on egd1btt1 cells expressing tagged Egd2 and expanded
polyglutamine for 6 and 20 hours. Egd2 could be localized to polyglutamine aggregates, in
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which case Egd2 would appear in and overlapping with punctate structures. Egd2 could be
localized to ribosomes, in which case expression would likely appear diffuse. Egd2 could be
acting in its role as a transcription factor (Shi et al., 1995), in which case it would be localized to
the nucleus. Any of these outcomes would present new insights into the mechanism by which the
egd1btt1 strain reduces aggregation and cytotoxicity.

4.2.2 Determining the mechanism by which second-site suppressors K24W
and K28G rescue prion propagation defect induced by LGMDD1-associated
mutations
Evaluate the ability of Sis1-K24W-F115I and Sis1-K28G-F115I to stimulate Hsp70 ATPase
activity
An important step in the Hsp40/70 cycle is the stimulation of Hsp70 ATPase activity by
Hsp40 (Craig & Marszalek et al., 2014). Hsp40 stimulation of Hsp70 ATPase activity regulates
Hsp70 binding to substrate. Furthermore, recent research has shown that inhibition of the HPDmotif, which is critical for ATPase stimulation by Hsp40, is beneficial in a LGMDD1 mouse
disease model (Bengoechea et al., 2020). We would hypothesize that because the K24W and
K28G mutations are located spatially proximal to the HPD-motif they will affect ATPase
stimulation of Hsp70 by Sis1-K24W-F115I and Sis1-K28G-F115I. In order to assess ATP
hydrolysis, Sis1-WT, Sis1-F115I, Sis1-K24W, Sis1-K28G, Sis1-K24W-F115I, and Sis1-K28GF115I would be purified and the various Sis1 substrates would be used to perform ATPase
assays with Ssa1 and [RNQ+] prion seeds.
Determine the ability of Sis1-K24W-F115I and Sis1-K28G-F115I to dimerize
Sis1 has been reported to dimerize through a dimerization domain located on the C-terminus of
the protein (Sha et al., 2000). Dimerization of the protein is vitally important for substrate
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binding of Sis1, and thus, of the Hsp40/70 cycle. Furthermore, it is known that dimerization is
reduced in many LGMDD1-associated mutants, including Sis1-F115I (Bhadra et al., in prep).
We hypothesize that the addition of either second-site suppressor will modulate dimerization of
Sis1. While the second-site suppressors are not located near the C-terminus they could still affect
the structure and stability of the dimer through intragenic and extragenic interactions. To do this
experiment Sis1-WT, Sis1-F115I, Sis1-K24W, Sis1-K28G, Sis1-K24W-F115I, and Sis1-K28GF115I would be purified and the resulting proteins would be used to conduct binding assays.
These binding assays would show dimerization efficiency of these proteins to make homodimers.
Furthermore, we could test the ability of the second-site suppressors to dimerize with Sis1-WT,
or in trans with the LGMDD1-associated mutation, such as testing the ability of Sis1-F115I to
dimerize with Sis1-K28G.
Determine the ability of Sis1-K24W-F115I and Sis1-K28G-F115I to act on substrate
Because Rnq1 is a known client protein of Sis1, Sis1 efficiency can be determined by
measuring the speed with which Rnq1 aggregates form in vitro. To do this the fluorescent
emission of Thioflavin T, which associates with beta-sheet rich structures, is measured. As more
[RNQ+] aggregates form the fluorescence emission of Thioflavin T increases. Binding of Sis1 to
Rnq1 slows formation of [RNQ+] aggregates, therefore Sis1 activity and effectiveness can be
determined based on the fluorescent emission of Thioflavin T. We would hypothesize that Sis1K24W-F115I and Sis1-K28G-F115I would show delayed [RNQ+] aggregation compared to Sis1F115I. This experiment would require isolation of Sis1-WT, Sis1-K24W, Sis1-K28G, Sis1F115I, Sis1-K24W-F115I, Sis1-K28G-F115I and unseeded RNQ monomer.

77

4.3 Conclusion
The previously outlined experiments are a basis for uncovering the mechanisms by which
NAC disruption and second-site suppressors improve the cellular protein folding environment in
the face of cellular stress. These experiments should aid in the discovery of relevant information
to further each of these projects and perhaps identify new therapeutic strategies for treating
neurodegenerative disorders and chaperonopathies. These experiments are crucial for furthering
our understanding of how NAC disruption and the second-site suppressors of LGMDD1associated mutants affect protein homeostasis.
In summation, this body of work identifies novel effects of chaperone modulation on
protein folding. NAC modulation is shown in this work to be a potential therapeutic strategy for
reducing expanded polyglutamine aggregation and toxicity. Likewise, two second-site
suppressors have been shown to rescue defects induced by LGMDD1 mutations and thus can be
evaluated for their potential as therapeutics to treat LGMDD1.
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